<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>

    <title>Pocket Medicine: The Massachusetts General Hospital Handbook of Internal Medicine</title>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
  <link rel="stylesheet" type="text/css" href="../stylesheet.css"/>
<link rel="stylesheet" type="text/css" href="../page_styles.css"/>

  


<link href="../calibreHtmlOutBasicCss.css" type="text/css" rel="stylesheet" />

</head>
<body>

<div class="calibreMeta">
  <div class="calibreMetaTitle">
  
  
    
    <h1>
      <a href="../../k34gmbu8.html">Pocket Medicine
</a>
    </h1>
    
    
  
  </div>
  <div class="calibreMetaAuthor">
    Marc Sabatine

  </div>
</div>

<div class="calibreMain">

  <div class="calibreEbookContent">
    
      <div class="calibreEbNavTop">
        
          <a href="part0006.html" class="calibreAPrev">previous page
</a>
        

        
          <a href="part0008.html" class="calibreANext">next page
</a>
        
      </div>
    

    
<h2 class="ct"><a id="h20" class="calibre7"></a><a id="page_2-1" class="calibre7"></a><a href="part0002.html#rh25" class="calibre7">DYSPNEA</a></h2>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre27"/>
<col class="calibre44"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b"><p class="tabhead"><b class="calibre4">Pathophysiology</b></p></td>
<td class="bg1-b"><p class="tabhead"><b class="calibre4">Etiologies</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Airway obstruction</b> (↑ resistance to airflow)</p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Asthma</b>, <b class="calibre4">COPD</b>, bronchiectasis, cystic fibrosis, tumor, foreign body, vocal cord dysfunction, anaphylaxis</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Alveolar / Parenchymal disease</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Pulmonary edema:</b> <i class="calibre3">cardiogenic</i> or <i class="calibre3">noncardiogenic</i></p>
<p class="tab"><b class="calibre4">ILD; pneumonia;</b> atelectasis</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Vascular</b></p>
<p class="tab">(V/Q mismatch)</p></td>
<td class="bg0-b"><p class="tab">Large vessel: <b class="calibre4">PE</b>, tumor emboli</p>
<p class="tab">Small vessel: <b class="calibre4">PHT</b>, vasculitis, ILD, emphysema, PNA</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Chest wall</b></p>
<p class="tab">(↑ resistance to expansion; weakness of respir. muscles)</p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Pleural disease:</b> large effusion, fibrosis, pneumothorax</p>
<p class="tab"><b class="calibre4">Chest wall/diaphragm:</b> kyphoscoliosis, ↑ abd girth</p>
<p class="tab"><b class="calibre4">Neuromuscular disorders</b> (ALS, GBS, MG)</p>
<p class="tab"><b class="calibre4">Hyperinflation</b> (COPD, asthma)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Stimulation of receptors</b></p></td>
<td class="bg0-b"><p class="tab">Chemoreceptors: <b class="calibre4">hypoxemia</b>, metabolic acidosis</p>
<p class="tab">Mechanoreceptors: <b class="calibre4">ILD</b>, <b class="calibre4">pulmonary edema</b>, PHT, PE</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">↓ <b class="calibre4">O<sub class="calibre13">2</sub> carrying cap.</b> (but nl P<sub class="calibre13">a</sub>O<sub class="calibre13">2</sub>)</p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Anemia</b>, methemoglobinemia, CO poisoning</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Psychological</b></p></td>
<td class="bg"><p class="tab">Anxiety, panic attack, depression, somatization</p></td>
</tr>
</table>
<p class="h2a">Evaluation</p>
<p class="bl"><span class="sbl">•</span> History: quality of sensation, tempo, positional dependence, exac./allev. factors, exertion</p>
<p class="bl"><span class="sbl">•</span> Cardiopulmonary exam, S<sub class="calibre8">a</sub>O<sub class="calibre8">2</sub>, CXR (see Appendix &amp; Radiology inserts), ECG, ABG, U/S predictors of CHF: h/o CHF, PND, S<sub class="calibre8">3</sub>, CXR w/ venous congestion, AF <span class="s1r">(<i class="calibre3">JAMA</i> 2005;294:1944)</span> dyspnea w/ nl CXR: CAD, asthma, PE, PHT, early ILD, anemia, acidosis, NM disease</p>
<p class="bl"><span class="sbl">•</span> Based on results of initial evaluation: PFT, chest CT, TTE, cardiopulmonary testing</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">BNP &amp; NT-proBNP</b> ↑ in CHF (also ↑ in AF, RV strain from PE, COPD flare, PHT, ARDS)</p>
<p class="bl1">BNP &lt;100 pg/mL to r/o CHF (90% Se), &gt;400 to r/i <span class="s1r">(<i class="calibre3">NEJM</i> 2002;347:161)</span></p>
<p class="bl1">NT-proBNP &lt;300 pg/mL to r/o CHF (99% Se); age-related cut points to r/i: &gt;450 pg/mL (&lt;50 y), &gt;900 (50–75 y), &gt;1800 (&gt;75 y) <span class="s1r">(<i class="calibre3">EHJ</i> 2006;27:330)</span></p>
<p class="bl1">In chronic heart failure, ∴ need to compare to known “dry BNP”</p>
<h2 class="ct"><a id="h21" class="calibre7"></a><a id="page_2-2" class="calibre7"></a><a href="part0002.html#rh26" class="calibre7">PULMONARY FUNCTION TESTS (PFTs)</a></h2>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Spirometry:</b> evaluate for obstructive disease</p>
<p class="bl1">Flow-volume loops: diagnose and/or localize obstruction</p>
<p class="bl1">Bronchodilator: indicated if obstruction at baseline or asthma clinically suspected</p>
<p class="bl1">Methacholine challenge: helps dx asthma if spirometry nl, &gt; 20% ↓ FEV<sub class="calibre8">1</sub> → asthma</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Lung volumes:</b> evaluate for hyperinflation or restrictive disease including NM causes</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">D<sub class="calibre8">L</sub>CO:</b> evaluates functional surface area for gas exchange; helps differentiate causes of obstructive and restrictive diseases and screens for vascular disease &amp; early ILD</p>
<p class="capf"><b class="calibre4">Figure 2-1</b> Approach to abnormal PFTs</p>
<p class="center"><img src="../images/00036.jpeg" alt="" class="calibre2"/></p>
<p class="fn">FEV<sub class="calibre13">1</sub>/FVC LLN typically 0.75. D<sub class="calibre13">L</sub>CO can be diminished due to secondary atelectasis.</p>
<h2 class="ct"><a id="h22" class="calibre7"></a><a href="part0002.html#rh27" class="calibre7">ASTHMA</a></h2>
<p class="h2a">Definition and epidemiology <span class="s">(<i class="calibre3">Lancet</i> 2018;391:783)</span></p>
<p class="bl"><span class="sbl">•</span> Chronic inflam disorder w/ <b class="calibre4">airway hyperresponsiveness</b> + <b class="calibre4">variable airflow obstruction</b></p>
<p class="bl"><span class="sbl">•</span> Affects 5–10% population; ~85% of cases by age 40 y</p>
<p class="h2a">Clinical manifestations <span class="s">(<i class="calibre3">NEJM</i> 2013;369:549)</span></p>
<p class="bl"><span class="sbl">•</span> Classic triad = <b class="calibre4">wheezing</b>, <b class="calibre4">cough, dyspnea;</b> others include chest tightness, sputum; symptoms typically <i class="calibre3">chronic</i> with <i class="calibre3">episodic exacerbation</i></p>
<p class="bl"><span class="sbl">•</span> Precipitants (<b class="calibre4">triggers</b>)</p>
<p class="bl1"><i class="calibre3">respiratory irritants</i> (smoke, perfume, etc.) &amp; <i class="calibre3">allergens</i> (pets, dust mites, pollen, etc.)</p>
<p class="bl1"><i class="calibre3">infections</i> (URI, bronchitis, sinusitis)</p>
<p class="bl1"><i class="calibre3">drugs</i> (eg, ASA &amp; NSAIDs via leukotrienes, βB via bronchospasm, MSO<sub class="calibre8">4</sub> via histamine)</p>
<p class="bl1">emotional stress, cold air, exercise (increase in ventilation dries out airways)</p>
<p class="h2a">Physical examination</p>
<p class="bl"><span class="sbl">•</span> Wheezing and prolonged expiratory phase</p>
<p class="bl"><span class="sbl">•</span> Presence of nasal polyps, rhinitis, rash → <i class="calibre3">allergic component</i></p>
<p class="bl"><span class="sbl">•</span> Exacerbation → ↑ RR, ↑ HR, accessory muscle use, diaphoresis, pulsus paradoxus</p>
<p class="h2a">Diagnostic studies <span class="s">(<i class="calibre3">JAMA</i> 2017;318:279)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Spirometry:</b> ↓ FEV<sub class="calibre8">1</sub>, ↓ FEV<sub class="calibre8">1</sub>/FVC, coved flow-volume loop; lung volumes: ± ↑ RV &amp; TLC</p>
<p class="bl1">⊕ bronchodilator response (↑ FEV<sub class="calibre8">1</sub> ≥12% &amp; ≥200 mL) strongly suggestive of asthma</p>
<p class="bl1">methacholine challenge (↓ FEV<sub class="calibre8">1</sub> ≥20%) if PFTs nl: Se &gt;90%</p>
<p class="bl"><span class="sbl">•</span> Allergy suspected → consider checking serum IgE, eos, skin testing/RAST</p>
<p class="h2a">Ddx <span class="s">(“all that wheezes is not asthma…”)</span></p>
<p class="bl"><span class="sbl">•</span> Hyperventilation &amp; panic attacks</p>
<p class="bl"><span class="sbl">•</span> Upper airway obstruction or inh foreign body; laryngeal/vocal cord dysfxn (eg, 2° to GERD)</p>
<p class="bl"><span class="sbl">•</span> CHF (“cardiac asthma”); COPD; bronchiectasis; ILD (including sarcoidosis); vasculitis; PE</p>
<p class="h2a">“Asthma plus” syndromes</p>
<p class="bl"><span class="sbl">•</span> Atopy = asthma + allergic rhinitis + atopic dermatitis</p>
<p class="bl"><span class="sbl">•</span> Aspirin-exacerbated respiratory disease (Samter’s syndrome) = asthma + ASA sensitivity + nasal polyps <span class="s1r">(<i class="calibre3">J Allergy Clin Immunol</i> 2015;135:676)</span></p>
<p class="bl"><span class="sbl">•</span> ABPA = asthma + pulmonary infiltrates + allergic rxn to <i class="calibre3">Aspergillus</i> <span class="s1r">(<i class="calibre3">Chest</i> 2009;135:805)</span></p>
<p class="bl1">Dx: ↑ IgE to <i class="calibre3">Asperg.</i> &amp; total (&gt;1000), ↑ <i class="calibre3">Asperg.</i> IgG levels, ↑ eos, central bronchiectasis</p>
<p class="bl1">Rx: steroids ± itra-/voriconazole for refractory cases <span class="s1r">(<i class="calibre3">NEJM</i> 2000;342:756)</span></p>
<p class="bl"><span class="sbl">•</span> Eosinophilic granulomatosis w/ polyangiitis (EGPA, previously Churg-Strauss) = asthma + eosinophilia + granulomatous vasculitis</p>
<p class="h">C<small class="calibre30">HRONIC</small> M<small class="calibre30">ANAGEMENT</small></p>
<p class="h2a">“Reliever” medications <span class="s">(used prn to quickly relieve sx)</span></p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Short-acting</i> inh β<sub class="calibre8"><b class="calibre4">2</b></sub><b class="calibre4">-agonists</b> (SABA): albuterol Rx of choice</p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Short-acting</i> inh <b class="calibre4">anticholinergics</b> (ipratropium) ↑ β<sub class="calibre8">2</sub>-agonist delivery → ↑ bronchodilation</p>
<p class="h2a">“Controller” meds <span class="s">(taken daily to keep control) (<i class="calibre3">JAMA</i> 2017;318:279)</span></p>
<p class="bl"><span class="sbl">•</span> Inh <b class="calibre4">corticosteroids</b> (ICS) Rx of choice. Superior to LAMA if sputum w/ ≥2% eos <span class="s1r">(<i class="calibre3">NEJM</i> 2019;380:2009)</span>. PO steroids may be needed for severely uncontrolled asthma; avoid if possible b/c of systemic side effects.</p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Long-acting</i> inh β<sub class="calibre8"><b class="calibre4">2</b></sub><b class="calibre4">-agonists</b> (LABA; eg, salmeterol) safe &amp; ↓ exacerbations when added to ICS <span class="s1r">(<i class="calibre3">NEJM</i> 2018;378:2497)</span></p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Long-acting</i> inh <b class="calibre4">antimuscarinics</b> (LAMA; eg, tiotropium, umeclidinium): may consider if sx despite ICS+LABA <span class="s1r">(<i class="calibre3">JAMA</i> 2018;319:1473)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Leukotriene receptor antagonists</b> (LTRA): some Pts very responsive, esp. ASA-sens <span class="s1r">(<i class="calibre3">AJRCCM</i> 2002;165:9)</span> and exercise-induced <span class="s1r">(<i class="calibre3">Annals</i> 2000;132:97)</span>. May be noninferior to ICS initial Rx and LABA add-on Rx <span class="s1r">(<i class="calibre3">NEJM</i> 2011;364:1695)</span>.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Nedocromil/cromolyn</b>: limited use in adults. Useful in young Pts, exercise-induced bronchospasm; ineffective unless used before trigger or exercise exposure.</p>
<p class="h2a">Immunotherapies <span class="s">(<i class="calibre3">NEJM</i> 2017;377:965)</span></p>
<p class="bl"><span class="sbl">•</span> Allergen ImmunoRx (“allergy shots”) may help if sig. allerg. component <span class="s1r">(<i class="calibre3">JAMA</i> 2016;315:1715)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Anti-IgE</b> (omalizumab) for uncontrolled mod-to-severe allergic asthma (w/ IgE &gt;30) on ICS ± LABA <span class="s1r">(<i class="calibre3">JAMA</i> 2017; 318:279)</span></p>
<p class="bl"><span class="sbl">•</span> Anti-IL5 (mepolizumab, reslizumab) ↓ exacerb in severe asthma <span class="s1r">(<i class="calibre3">NEJM</i> 2014;371:1189 &amp; 1198)</span></p>
<p class="bl"><span class="sbl">•</span> Anti-IL5Rα (benralizumab) ↓ steroid use, ↓ exac. in sev asthma w/ eos <span class="s1r">(<i class="calibre3">NEJM</i> 2017;376:2448)</span></p>
<p class="bl"><span class="sbl">•</span> Anti-IL4Rα (dupilumab) blocks IL-4 &amp; IL-13; ↓ exacerb in severe asthma, ↓ steroid use, ↑ FEV<sub class="calibre8">1</sub> <span class="s1r">(<i class="calibre3">NEJM</i> 2018;378:2475 &amp; 2486)</span></p>
<p class="h2a"><a id="page_2-3" class="calibre1"></a>Principles of treatment</p>
<p class="bl"><span class="sbl">•</span> Education and avoidance of environmental triggers <span class="s1r">(<i class="calibre3">Lancet</i> 2015;386:1075)</span>; yearly flu shot</p>
<p class="bl"><span class="sbl">•</span> Use quick-relief rescue medication as needed for all Pts</p>
<p class="bl"><span class="sbl">•</span> Goal to achieve <b class="calibre4">complete control</b> = daily sx ≤2/wk, ∅ nocturnal sx or limitation of activity, reliever med ≤2/wk, nl peak expiratory flow rate or FEV<sub class="calibre8">1</sub>; partly controlled = 1–2 of the above present in a wk; uncontrolled = ≥3 of the above present in a wk</p>
<p class="bl"><span class="sbl">•</span> Step up treatment as needed to gain control, step down as tolerated</p>
<p class="bl"><span class="sbl">•</span> Can abort exacerb by quadrupling ICS if deteriorating control <span class="s1r">(<i class="calibre3">NEJM</i> 2018;378:902)</span></p>
<p class="image1"><img src="../images/00037.jpeg" alt="" class="calibre2"/></p>
<p class="h">E<small class="calibre30">XACERBATION</small></p>
<p class="h2a">Evaluation</p>
<p class="bl"><span class="sbl">•</span> History: baseline PEF, steroid requirement, ED visits, hospital admissions, prior intubation</p>
<p class="bl1">Current exacerbation: duration, severity, potential precipitants, meds used</p>
<p class="bl1"><i class="calibre3">Risk factors for life-threatening:</i> prior intubation, h/o near-fatal asthma, ED visit/hosp for asthma w/in 1 y, current/recent PO steroids, not using ICS, overdependent on SABA, Ψ, h/o noncompliance</p>
<p class="bl"><span class="sbl">•</span> Physical exam: VS, pulm, accessory muscle use, pulsus paradoxus, abdominal paradox</p>
<p class="bl1">Assess for barotrauma: asymmetric breath sounds, tracheal deviation, subcutaneous air → pneumothorax, precordial (Hamman’s) crunch → pneumomediastinum</p>
<p class="bl"><span class="sbl">•</span> Diagnostic studies: <b class="calibre4">peak expiratory flow</b> (know personal best; &lt;80% personal best c/w poor control, &lt;50% c/w severe exacerbation); <b class="calibre4">S</b><sub class="calibre8"><b class="calibre4">a</b></sub><b class="calibre4">O</b><sub class="calibre8"><b class="calibre4">2</b></sub>; <b class="calibre4">CXR</b> to r/o PNA or PTX; ABG if severe (low P<sub class="calibre8">a</sub>CO<sub class="calibre8">2</sub> initially; nl or high P<sub class="calibre8">a</sub>CO<sub class="calibre8">2</sub> <i class="calibre3">may</i> signify tiring)</p>
<p class="imagef"><img src="../images/00038.jpeg" alt="" class="calibre2"/></p>
<p class="fn"><b class="calibre4"><i class="calibre3">Resp arrest imminent</i>:</b> drowsy, abdominal paradox, wheezes inaudible (b/c ∅ air movement), bradycardia, loss of abdominal paradox (respiratory muscle fatigue). Presence of several parameters (not necessarily all) indicates classification (adapted from GINA 2019 update).</p>
<p class="h2a">Initial treatment <span class="s">(<i class="calibre3">NEJM</i> 2010;363:755)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Oxygen</b> to keep S<sub class="calibre8">a</sub>O<sub class="calibre8">2</sub> ≥90%</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Inhaled SABA</b> (eg, albuterol) by MDI (4–8 puffs) or nebulizer (2.5–5 mg) q20min</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Corticosteroids:</b> prednisone 40-60 mg PO if outPt; methylpred IV if ED or inPt</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Ipratropium</b> MDI (4–6 puffs) or nebulizer (0.5 mg) q20min if severe <span class="s1r">(<i class="calibre3">Chest</i> 2002;121:1977)</span></p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Reassess after 60–90 min of Rx</i></p>
<p class="bl1">Mild-mod exacerbation: cont SABA q1h</p>
<p class="bl1">Sev exacerbation: SABA &amp; ipratropium q1h or cont.; if refractory, consider Mg ± heliox</p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Decide disposition within 4 h of presentation and after 1–3 h of Rx</i></p>
<p class="capf"><a id="page_2-4" class="calibre1"></a><b class="calibre4">Figure 2-2</b> Disposition of patients after initial treatment of asthma exacerbation</p>
<p class="center"><img src="../images/00039.jpeg" alt="" class="calibre2"/></p>
<p class="fn">ICU-level care</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">High-dose steroids:</b> methylpred 125 mg IV q6h <span class="s1r">(<i class="calibre3">NEJM</i> 1999;340:1941)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Invasive ventilation:</b></p>
<p class="bl1">Large ET tube, P<sub class="calibre8">plat</sub> &lt;30 cm H<sub class="calibre8">2</sub>O (predicts barotrauma better than PIP), max exp time</p>
<p class="bl1">PEEP individualized to patient physiology</p>
<p class="bl1">Paralysis, inhalational anesthetics, bronchoalveolar lavage w/ mucolytic, heliox (60–80% helium) and ECMO have been used with success</p>
<p class="bl"><span class="sbl">•</span> NPPV likely improves obstruction <span class="s1r">(<i class="calibre3">Chest</i> 2003;123:1018)</span>, but controversial and rarely used</p>
<h2 class="ct"><a id="h23" class="calibre7"></a><a href="part0002.html#rh28" class="calibre7">ANAPHYLAXIS</a></h2>
<p class="h2a">Definition and pathophysiology <span class="s">(<i class="calibre3">Ann Emerg Med</i> 2006;47:373)</span></p>
<p class="bl"><span class="sbl">•</span> Severe, rapid onset (mins to hrs), potentially life-threatening systemic allergic response</p>
<p class="bl"><span class="sbl">•</span> IgE-mediated mast cell degranulation with release of histamine, tryptase, and TNF</p>
<p class="bl"><span class="sbl">•</span> Precipitates systemic reactions (bronchospasm, tissue swelling, fluid shifts, vasodilation)</p>
<p class="bl"><span class="sbl">•</span> Common triggers: penicillins, cephalosporins, shellfish, nuts, insect stings, IV contrast (not truly an IgE-mediated mechanism, but clinically similar)</p>
<p class="h2a">Diagnosis: <span class="s">any of the three following criteria</span></p>
<p class="bl"><span class="sbl">1)</span> Acute illness with skin ± mucosal involvement (rash, flushing, hives), AND at least one of:</p>
<p class="bl1">Respiratory compromise (wheeze, stridor, dyspnea, hypoxemia)</p>
<p class="bl1">Hypotension or hypoperfusion (syncope, incontinence)</p>
<p class="bl"><span class="sbl">2)</span> Two or more of the following after exposure to a <b class="calibre4">likely</b> allergen: skin/mucosal involvement, respiratory compromise, ↓ BP or hypoperfusion, GI symptoms</p>
<p class="bl"><span class="sbl">3)</span> Hypotension after exposure to <b class="calibre4">known</b> allergen for that Pt</p>
<p class="h2a">Treatment</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Epi:</b> IM 0.3–0.5 mL of 1:1000 dilution q5–20min; gtt at 0.1 mcg/kg/min if HoTN; avoid IVB</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Airway:</b> suppl O<sub class="calibre8">2</sub> ± intubation or cricothyroidotomy (if laryngeal edema); β<sub class="calibre8">2</sub>-agonists</p>
<p class="bl"><span class="sbl">•</span> Fluid resuscitation w/ ≥1–2 L crystalloid (may extravasate up to 35% of intravasc volume)</p>
<p class="bl"><span class="sbl">•</span> Antihistamines relieve hives &amp; itching, <i class="calibre3">no effect on airway or hemodynamics</i>; H1RA (diphenhydramine 50 mg IV/IM) ± H2RA (ranitidine 50 mg IV)</p>
<p class="bl"><span class="sbl">•</span> Steroids w/o immediate effect but may help prevent relapse: methylpred 125 mg IV q6h</p>
<p class="bl"><span class="sbl">•</span> Avoid unopposed α-adrenergic vasopressors</p>
<p class="h2a">Disposition</p>
<p class="bl"><span class="sbl">•</span> Mild rxn limited to urticaria or mild bronchospasm can be observed for ≥6 h; admit all others</p>
<p class="bl"><span class="sbl">•</span> Watch for <b class="calibre4">biphasic reaction;</b> occurs in 23%, typically w/in 8–10 h but up to 72 h</p>
<p class="h2a">Angioedema <span class="s">(<i class="calibre3">J Allergy Clin Immunol</i> 2013;131:1491)</span></p>
<p class="bl"><span class="sbl">•</span> Localized swelling of skin/mucosa; involves face, lips, tongue, uvula, larynx, and bowels</p>
<p class="bl"><span class="sbl">•</span> Etiologies: mast cell-mediated (eg, NSAIDs); bradykinin-mediated (eg, <b class="calibre4">ACEi</b>, ARNi, hereditary angioedema, acquired C1 inhibitor deficiency); idiopathic</p>
<p class="bl"><span class="sbl">•</span> Diagnosis: C4 and C1 inhibitor level, tryptase (if suspect anaphylaxis), ESR/CRP</p>
<p class="bl"><span class="sbl">•</span> Rx: intubation if risk of airway compromise. Allergic angioedema: H1/H2 antihist., steroids.</p>
<p class="bl1">If 2° ACEi: d/c ACEi, antihist., icatibant (bradykinin-receptor antag; <i class="calibre3">NEJM</i> 2015;372:418).</p>
<p class="bl1">Hereditary angioedema: plasma-derived C1 inhibitor <span class="s1r">(<i class="calibre3">NEJM</i> 2010;363:513)</span>, ecallantide (kallikrein inhibitor; <i class="calibre3">NEJM</i> 2010;363:523).</p>
<h2 class="ct"><a id="h24" class="calibre7"></a><a id="page_2-5" class="calibre7"></a><a href="part0002.html#rh29" class="calibre7">CHRONIC OBSTRUCTIVE PULMONARY DISEASE</a></h2>
<p class="h2a">Definition and epidemiology <span class="s">(<i class="calibre3">Lancet</i> 2017;389:1931)</span></p>
<p class="bl"><span class="sbl">•</span> Progressive airflow limitation caused by airway and parenchymal inflammation</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre45"/>
<col class="calibre46"/>
<col class="calibre46"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3">
<p class="tabheadc"><b class="calibre4">Emphysema vs. Chronic Bronchitis</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"> </p></td>
<td class="bg0-br"><p class="tabhead">Emphysema</p></td>
<td class="bg0-b"><p class="tabhead">Chronic Bronchitis</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Definition</b></p></td>
<td class="bg0-br"><p class="tab">Dilation/destruction of parenchyma (path definition)</p></td>
<td class="bg0-b"><p class="tab">Productive cough &gt;3 mo/y × ≥2 y (clinical definition)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Pathophysiology</b></p></td>
<td class="bg0-br"><p class="tab">Tissue destruction</p>
<p class="tab">V/Q: ↑ dead space fraction → hypercarbia, but only mild hypoxemia</p></td>
<td class="bg0-b"><p class="tab">Small airways affected V/Q: ↑ shunt fraction → severe hypoxemia, hypercapnia PHT, cor pulmonale</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Clinical manifestations</b></p></td>
<td class="bg0-br"><p class="tab">Severe, constant dyspnea</p>
<p class="tab">Mild cough</p></td>
<td class="bg0-b"><p class="tab">Intermittent dyspnea</p>
<p class="tab">Copious sputum production</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Physical exam</b></p></td>
<td class="bg0-r"><p class="tab">“Pink puffer”</p>
<p class="tab">Tachypneic, noncyanotic, thin</p>
<p class="tab">Diminished breath sounds</p></td>
<td class="bg"><p class="tab">“Blue bloater”</p>
<p class="tab">Cyanotic, obese, edematous</p>
<p class="tab">Rhonchi &amp; wheezes</p></td>
</tr>
</table>
<p class="h2a">Pathogenesis <span class="s">(<i class="calibre3">Lancet</i> 2017;389:1931)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Cigarette smoke</b> (centrilobular emphysema, affects 15–20% of smokers)</p>
<p class="bl"><span class="sbl">•</span> Recurrent airway infections</p>
<p class="bl"><span class="sbl">•</span> α<sub class="calibre8">1</sub>-antitrypsin deficiency: early-onset panacinar emphysema, 1–3% of COPD cases. Suspect if age &lt;45, lower lungs affected, extrathoracic manifestations (liver disease [not if MZ subtype], FMD, pancreatitis). ✔ serum AAT level (nb, acute phase reactant).</p>
<p class="bl"><span class="sbl">•</span> Low FEV<sub class="calibre8">1</sub> in early adulthood associated w/ COPD <span class="s1r">(<i class="calibre3">NEJM</i> 2015;373:111)</span></p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> Chronic cough, sputum production, dyspnea; later stages → freq exacerb, AM HA, wt loss</p>
<p class="bl"><span class="sbl">•</span> Exacerbation triggers: infxn, other cardiopulmonary disease, including PE</p>
<p class="bl1">Infxn: overt tracheobronchitis/pneumonia from viruses, <i class="calibre3">S. pneumoniae</i>, <i class="calibre3">H. influenzae</i>, <i class="calibre3">M. catarrhalis</i> or triggered by changes in strain of colonizers <span class="s1r">(<i class="calibre3">NEJM</i> 2008;359:2355)</span></p>
<p class="bl"><span class="sbl">•</span> Physical exam: ↑ AP diameter of chest (“barrel chest”), hyperresonance, ↓ diaphragmatic</p>
<p class="bl1">excursion, ↓ breath sounds, ↑ expiratory phase, rhonchi, wheezes</p>
<p class="bl1">during exacerbation: tachypnea, accessory muscle use, pulsus paradoxus, cyanosis</p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Asthma-COPD overlap syndrome</i> (ACOS; <i class="calibre3">NEJM</i> 2015;373:1241): features of both present. For example: reversibility of airway obstruction w/ bronchodilator in COPD; neutrophilic inflammation in asthma (more classic in COPD); eos in COPD</p>
<p class="h2a">Diagnostic studies <span class="s">(<i class="calibre3">JAMA</i> 2019;321:786)</span></p>
<p class="bl"><span class="sbl">•</span> CXR (see Radiology inserts): hyperinflation, flat diaphragms, ± interstitial markings &amp; bullae</p>
<p class="bl"><span class="sbl">•</span> PFTs: <b class="calibre4">obstruction:</b> ↓↓ FEV<sub class="calibre8">1</sub>, ↓ FVC, <b class="calibre4">FEV<sub class="calibre8">1</sub>/FVC</b> &lt;<b class="calibre4">0.7 (no sig</b> Δ <b class="calibre4">post bronchodilator)</b>, expiratory scooping of flow-volume loop; <b class="calibre4">hyperinflation:</b> ↑↑ RV, ↑ TLC, ↑ RV/TLC;</p>
<p class="bl1"><b class="calibre4">abnormal gas exchange:</b> ↓ D<sub class="calibre8">L</sub>CO (in emphysema)</p>
<p class="bl"><span class="sbl">•</span> ABG: ↓ P<sub class="calibre8">a</sub>O<sub class="calibre8">2</sub>, ± ↑ P<sub class="calibre8">a</sub>CO<sub class="calibre8">2</sub> (in chronic bronchitis, usually only if FEV<sub class="calibre8">1</sub> &lt;1.5 L) and ↓ pH</p>
<p class="bl"><span class="sbl">•</span> Screen <i class="calibre3">symptomatic</i> Pts w/ spirometry; don’t screen if asx; screen for α1-AT deficiency</p>
<p class="h2a">Chronic treatment <span class="s">(<i class="calibre3">JAMA</i> 2019;321:786)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Bronchodilators</b> (<i class="calibre3">1</i><sup class="calibre15"><i class="calibre22">st</i></sup><i class="calibre3">-line</i>): <b class="calibre4">long-acting muscarinic antag (LAMA)</b>, β<sub class="calibre8">2</sub>-agonists (LABA)</p>
<p class="bl1">LAMA (eg, tiotropium): ↓ exacerb, slows ↓ FEV<sub class="calibre8">1</sub>, ↓ admit, ↓ resp failure; better than ipratropium or LABA <span class="s1r">(<i class="calibre3">NEJM</i> 2008;359:1543; 2011;364:1093; 2017;377:923)</span></p>
<p class="bl1">LABA: ~11% ↓ in exacerbations, no ↑ in CV events <span class="s1r">(<i class="calibre3">Lancet</i> 2016;387:1817)</span></p>
<p class="bl1">LAMA + LABA: ↑ FEV<sub class="calibre8">1</sub>, ↓ sx vs. either alone <span class="s1r">(<i class="calibre3">Chest</i> 2014;145:981)</span> and superior to LABA + inh steroid <span class="s1r">(<i class="calibre3">NEJM</i> 2016;374:2222)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Corticosteroids</b> (inhaled, ICS): ~11% ↓ in exacerbations &amp; slows ↓ FEV<sub class="calibre8">1</sub>; no Δ in risk of PNA or in mortality <span class="s1r">(<i class="calibre3">Lancet</i> 2016;387:1817)</span></p>
<p class="bl"><span class="sbl">•</span> “Triple Therapy” (ICS-LAMA-LABA) ↓ exac, ↓ hosp, ↑ PNA <span class="s1r">(<i class="calibre3">Lancet</i> 2016;388:963 &amp; 2018;391:1076; <i class="calibre3">NEJM</i> 2018; 378:1671)</span></p>
<p class="bl"><span class="sbl">•</span> Roflumilast (PDE-4 inhib) + bronchodil: ↑ FEV<sub class="calibre8">1</sub>, ↓ exacerb <span class="s1r">(<i class="calibre3">Lancet</i> 2015;385:857)</span></p>
<p class="bl"><span class="sbl">•</span> Anti-IL5 (eg, mepolizumab, benralizumab): mixed data on ↓ exacerb in Pts w/ eos <span class="s1r">(<i class="calibre3">NEJM</i> 2017;377:1613 &amp; 2019;DOI:10.1056/NEJMoa1905248)</span></p>
<p class="bl"><span class="sbl">•</span> Antibiotics: daily azithro ↓ exacerbations, but not routine <span class="s1r">(<i class="calibre3">JAMA</i> 2014;311:2225)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Oxygen:</b> if P<sub class="calibre8">a</sub>O<sub class="calibre8">2</sub> ≤55 mmHg or S<sub class="calibre8">a</sub>O<sub class="calibre8">2</sub> ≤89% (during rest, exercise, or sleep) to prevent cor</p>
<p class="bl1">pulmonale; only Rx proven to ↓ mortality <span class="s1r">(<i class="calibre3">Annals</i> 1980;93:391; <i class="calibre3">Lancet</i> 1981;i:681)</span>; no benefit in Pts w/ moderate hypoxemia (S<sub class="calibre8">a</sub>O<sub class="calibre8">2</sub> 89–93%) <span class="s1r">(<i class="calibre3">NEJM</i> 2016;375:1617)</span></p>
<p class="bl"><span class="sbl">•</span> NPPV if recent exacerb &amp; P<sub class="calibre8">a</sub>CO<sub class="calibre8">2</sub> &gt;53 ↓ risk of readmit or death <span class="s1r">(<i class="calibre3">JAMA</i> 2017;317:2177)</span></p>
<p class="bl"><a id="page_2-6" class="calibre1"></a><span class="sbl">•</span> <b class="calibre4">Prevention:</b> Flu/Pneumovax; smoking cessation → 50% ↓ in lung function decline <span class="s1r">(<i class="calibre3">AJRCCM</i> 2002;166:675)</span> and ↓ long-term mortality <span class="s1r">(<i class="calibre3">Annals</i> 2005;142:223)</span></p>
<p class="bl"><span class="sbl">•</span> Rehabilitation: ↓ dyspnea and fatigue, ↑ exercise tolerance, ↓ QoL <span class="s1r">(<i class="calibre3">NEJM</i> 2009;360:1329)</span></p>
<p class="bl"><span class="sbl">•</span> Surgery &amp; bronchoscopic interventions</p>
<p class="bl1">Lung volume reduction surgery: ↑ exercise capacity, ↓ mortality <i class="calibre3">if</i> FEV<sub class="calibre8">1</sub> &gt;20%, upper lobe, low exercise capacity <span class="s1r">(<i class="calibre3">NEJM</i> 2003;348:2059)</span></p>
<p class="bl1">Bronchoscopic lung reduction w/ endobronchial valves or coils: ↑ lung fxn but significant complications (PTX, PNA) <span class="s1r">(<i class="calibre3">NEJM</i> 2015;373:2325; <i class="calibre3">Lancet</i> 2015;386:1066; <i class="calibre3">JAMA</i> 2016;315175)</span></p>
<p class="bl"><span class="sbl">•</span> Lung transplant: ↑ QoL and ↓ sx <span class="s1r">(<i class="calibre3">Lancet</i> 1998;351:24)</span>, ? survival benefit <span class="s1r">(<i class="calibre3">Am J Transplant</i> 2009;9:1640)</span></p>
<p class="h2a">Staging and prognosis</p>
<p class="bl"><span class="sbl">•</span> Assess breathlessness, cough, sputum, exercise capacity &amp; energy (tools such as CAT and mMRC may be used as part of assessment)</p>
<p class="bl"><span class="sbl">•</span> Ratio of diam PA/aorta &gt;1 associated with ~3× ↑ risk of exacerbations <span class="s1r">(<i class="calibre3">NEJM</i> 2012;367:913)</span></p>
<p class="imagef"><img src="../images/00040.jpeg" alt="" class="calibre2"/></p>
<p class="fn">Smoking cessation &amp; vaccinations in all. Pulm rehab in groups B–D. O<sub class="calibre13">2</sub> as indicated per S<sub class="calibre13">a</sub>O<sub class="calibre13">2</sub>. (Adapted from GOLD Executive Summary [<i class="calibre3">AJRCCM</i> 2017;195:557])</p>
<p class="h">E<small class="calibre30">XACERBATION</small></p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre17"/>
<col class="calibre17"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabheadc"><b class="calibre4">COPD Exacerbation Treatment</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabhead">Agent</p></td>
<td class="bg0-br"><p class="tabhead">Dose</p></td>
<td class="bg0-b"><p class="tabhead">Comments</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Ipratropium</b></p></td>
<td class="bg0-br"><p class="tab">MDI 4–8 puffs q1–2h <i class="calibre3">or</i></p>
<p class="tab">Nebulizer 0.5 mg q1–2h</p></td>
<td class="bg0-b"><p class="tab">First-line therapy (<span class="tfont"><i class="calibre3">NEJM</i> 2011;364:1093</span>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Albuterol</b></p></td>
<td class="bg0-br"><p class="tab">MDI 4–8 puffs q1–2h <i class="calibre3">or</i></p>
<p class="tab">Nebulizer 2.5–5 mg q1–2h</p></td>
<td class="bg0-b"><p class="tab">Benefit if component of reversible bronchoconstriction</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Corticosteroids</b></p></td>
<td class="bg0-br"><p class="tabh">Prednisone 40 mg/d × 5d (<span class="tfont"><i class="calibre3">JAMA</i> 2013;309:2223</span>); some Pts will benefit from higher dose/longer course if severe</p>
<p class="tabh">Methylprednisolone 125 mg IV q6h × 72 h for more severe exacerbations</p></td>
<td class="bg0-b"><p class="tab">↓ treatment failure, ↓ hosp. stay</p>
<p class="tab">↑ FEV<sub class="calibre13">1</sub> but no mortality benefit,</p>
<p class="tabh">↑ complications (<span class="tfont"><i class="calibre3">Cochrane</i> 2009:CD001288</span>)</p>
<p class="tabh">OutPt Rx after ED visit ↓ relapse (<span class="tfont"><i class="calibre3">NEJM</i> 2003;348:2618</span>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Antibiotics</b></p></td>
<td class="bg0-br"><p class="tab">Amox, TMP-SMX, doxy, clarithro, antipneumococcal FQ all reasonable (no single abx proven superior). Consider local flora and avoid repeat courses of same abx. ≤5d course likely enough for mild-mod exacerbation (<span class="tfont"><i class="calibre3">JAMA</i> 2010;303:2035</span>).</p></td>
<td class="bg0-b"><p class="tab"><i class="calibre3">H. flu</i>, <i class="calibre3">M. catarrhalis</i>, <i class="calibre3">S. pneumo</i></p>
<p class="tabh">↑ PEF, ↓ Rx failure, ? ↓ short-term mort, ↓ subseq exacerb (<span class="tfont"><i class="calibre3">Chest</i> 2008;133:756 &amp; 2013;143:82</span>)</p>
<p class="tabh">Consider if ↑ sputum purulence or CRP &gt;40 (<span class="tfont"><i class="calibre3">Chest</i> 2013;144:1571</span>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Oxygenation</b></p></td>
<td class="bg0-br"><p class="tab">↑ F<sub class="calibre13">i</sub>O<sub class="calibre13">2</sub> to achieve P<sub class="calibre13">a</sub>O<sub class="calibre13">2</sub> ≥55–60 <i class="calibre3">or</i> S<sub class="calibre13">a</sub>O<sub class="calibre13">2</sub> 90–93%</p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Watch for CO<sub class="calibre13">2</sub> retention</b> (due to ↑ V/Q mismatch, loss of hypoxemic resp drive, Haldane effect) <i class="calibre3">but must maintain oxygenation!</i></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Noninvasive positive-pressure ventilation</b></p></td>
<td class="bg0-b" colspan="2"><p class="tab">Initiate <i class="calibre3">early</i> if moderate/severe dyspnea, ↓ pH / ↑ P<sub class="calibre13">a</sub>CO<sub class="calibre13">2</sub>, RR &gt;25</p>
<p class="tab">Results in 58% ↓ intubation, ↓ LOS by 3.2 d, 59% ↓ mortality</p>
<p class="tabh">Contraindications: Δ MS, inability to cooperate or clear secretions, hemodynamic instability, UGIB</p>
<p class="tab">(<span class="tfont"><i class="calibre3">NEJM</i> 1995;333:817; <i class="calibre3">Annals</i> 2003;138:861; <i class="calibre3">Cochrane</i> 2004;CD004104; <i class="calibre3">ERJ</i> 2005;25:348</span>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Endotracheal intubation</b></p></td>
<td class="bg0-b" colspan="2"><p class="tab">Consider if P<sub class="calibre13">a</sub>O<sub class="calibre13">2</sub> &lt;55–60, ↑‘ing P<sub class="calibre13">a</sub>CO<sub class="calibre13">2</sub>, ↓‘ing pH, ↑ RR, respiratory</p>
<p class="tab">fatigue, Δ MS or hemodynamic instability</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Other measures</b></p></td>
<td class="bg0-b" colspan="2"><p class="tab">Mucolytics overall not supported by data (<span class="tfont"><i class="calibre3">Chest</i> 2001;119:1190</span>)</p>
<p class="tab">Monitor for cardiac arrhythmias</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Post-exacerb care</b></p></td>
<td class="bg" colspan="2"><p class="tab">Follow up w/in 1 mo; smoking cessation if current smoker; vaccinations (influenza, pneumococcal), referral to pulm rehab (<span class="tfont"><i class="calibre3">AJRCCM</i> 2007;176:532</span>)</p></td>
</tr>
</table>
<h2 class="ct"><a id="h25" class="calibre7"></a><a id="page_2-7" class="calibre7"></a><a href="part0002.html#rh30" class="calibre7">SOLITARY PULMONARY NODULE</a></h2>
<p class="h2a">Principles</p>
<p class="bl"><span class="sbl">•</span> Definition: single, well-defined, &lt;3 cm, surrounded by nl lung, no LAN or pleural effusion</p>
<p class="bl"><span class="sbl">•</span> Often “incidentalomas,” esp with ↑ CT use, but may still be early, curable malignancy</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre36"/>
<col class="calibre43"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc">Etiologies</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Benign</b> (<b class="calibre4">70%</b>)</p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Malignant</b> (<b class="calibre4">30%</b>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Granuloma</b> (80%): TB, histo, coccidio</p>
<p class="tab"><b class="calibre4">Hamartoma</b> (10%)</p>
<p class="tab">Bronchogenic cyst, AVM, pulm infarct</p>
<p class="tab">Echinococcosis, ascariasis, aspergilloma</p>
<p class="tab">GPA, rheumatoid nodule, sarcoidosis</p>
<p class="tab">Lipoma, fibroma, amyloidoma</p></td>
<td class="bg"><p class="tab"><b class="calibre4">Bronchogenic carcinoma</b> (75%) periph: adeno (most common) &amp; large cell central: squamous &amp; small cell</p>
<p class="tab"><b class="calibre4">Metastatic</b> (20%): sarcoma, melanoma, breast, head &amp; neck, colon, testicular, renal</p>
<p class="tab">Carcinoid, primary sarcoma</p></td>
</tr>
</table>
<p class="h2a">Initial evaluation</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">History:</b> h/o cancer, smoking, age (&lt;30 y = 2% malignant, +15% each decade &gt;30)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">CT:</b> size/shape, Ca<sup class="calibre15">2</sup><sup class="calibre15">+</sup>, LAN, effusions, bony destruction, <b class="calibre4">compare w/ old studies</b></p>
<p class="bl1">∅ Ca → ↑ likelihood malignant; laminated → granuloma; “popcorn” → hamartoma</p>
<p class="bl"><span class="sbl">•</span> High-risk features for malig: size (eg, ≥2.3 cm diameter), spiculated, upper lobe, ♀, &gt;60 yo, &gt;1 ppd current smoker, no prior smoking cessation <span class="s1r">(<i class="calibre3">NEJM</i> 2003;348:2535 &amp; 2013;369:910)</span></p>
<p class="h2a">Diagnostic studies</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">PET:</b> detects metabolic activity of tumors, 97% Se &amp; 78% Sp for malig (esp if &gt;8 mm)</p>
<p class="bl1">useful for surgical staging b/c may detect unsuspected mets <span class="s1r">(<i class="calibre3">JAMA</i> 2001;285:914)</span></p>
<p class="bl1">useful in deciding which lesions to bx vs. follow w/ serial CT <span class="s1r">(<i class="calibre3">J Thor Oncol</i> 2006;1:71)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Transthoracic needle biopsy</b> (TTNB): if tech feasible, 97% will obtain definitive tissue dx <span class="s1r">(<i class="calibre3">AJR</i> 2005;185:1294)</span>; if noninformative or malignant → resect</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Video-assisted thoracoscopic surgery</b> (VATS): for percutaneously inaccessible lesions; highly sensitive and allows resection; has replaced thoracotomy</p>
<p class="bl"><span class="sbl">•</span> Transbronchial bx (TBB): most lesions too small to reliably sample w/o endobronchial</p>
<p class="bl1">U/S <span class="s1r">(<i class="calibre3">Chest</i> 2003;123:604)</span>; bronch w/ brushings low-yield unless invading bronchus;</p>
<p class="bl1">navigational bronchoscopy w/ 70% yield, ↑ sens w/ larger nodules <span class="s1r">(<i class="calibre3">Chest</i> 2012;142:385)</span></p>
<p class="bl"><span class="sbl">•</span> PPD, fungal serologies, ANCA</p>
<p class="h2a">Management <span class="s">(if</span> &gt;<span class="s">8 mm; if ≤8 mm, serial CT q6-12mo) (<i class="calibre3">Chest</i> 2013;143:840)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Low risk</b> (&lt;5%, see ref): serial CT (freq depending on risk); shared decision w/ Pt re: bx</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Intermediate risk</b> (5–60%): PET; if → follow low-risk protocol, if ⊕ → high-risk protocol</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">High risk</b> (and surgical candidate): TBB, TTNB, or VATS → lobectomy if malignant</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Ground-glass nodules:</b> longer f/u (b/c if malignant can be slow-growing) &amp; PET</p>
<h2 class="ct"><a id="h26" class="calibre7"></a><a href="part0002.html#rh31" class="calibre7">HEMOPTYSIS</a></h2>
<p class="h2a">Definition and pathophysiology</p>
<p class="bl"><span class="sbl">•</span> Expectoration of blood or blood-streaked sputum</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Massive hemoptysis:</b> &gt;100 mL/h or &gt;500 mL in 24 h; massive hemoptysis usually from tortuous or invaded bronchial arteries</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc">Etiologies (<span class="tfont1"><i class="calibre3">Crit Care Med</i> 2000;28:1642</span>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Infection/ Inflammation</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Bronchitis</b> (most common cause of trivial hemoptysis)</p>
<p class="tab"><b class="calibre4">Bronchiectasis</b> incl <b class="calibre4">CF</b> (common cause of massive hemoptysis)</p>
<p class="tab">TB or aspergilloma (can be massive); pneumonia or lung abscess</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Neoplasm</b></p></td>
<td class="bg0-b"><p class="tab">Usually primary <b class="calibre4">lung cancer</b>, sometimes metastasis (can be massive)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Cardiovasc</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">PE</b> (can be massive), pulmonary artery rupture (2° to instrumentation), CHF, mitral stenosis, trauma/foreign body, bronchovascular fistula</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Other</b></p></td>
<td class="bg"><p class="tab"><b class="calibre4">Vasculitis</b> (GPA, Goodpasture’s, Behçet’s), AVM, anticoag (w/ underlying lung dis), coagulopathy, cocaine, pulm hemosiderosis</p></td>
</tr>
</table>
<p class="h2a">Diagnostic workup</p>
<p class="bl"><span class="sbl">•</span> Localize bleeding site (r/o <i class="calibre3">GI or ENT source</i> by H&amp;P ± endo); determine whether <b class="calibre4">unilateral or bilateral, localized or diffuse, parenchymal or airway</b> by CXR/chest CT ± bronch</p>
<p class="bl"><span class="sbl">•</span> PT, PTT, CBC to rule out <b class="calibre4">coagulopathy</b></p>
<p class="bl"><span class="sbl">•</span> Sputum culture/stain for bacteria, fungi and AFB; cytology to <b class="calibre4">r/o malignancy</b></p>
<p class="bl"><span class="sbl">•</span> ANCA, anti-GBM, urinalysis to ✔ for <b class="calibre4">vasculitis</b> or <b class="calibre4">pulmonary-renal syndrome</b></p>
<p class="h2a"><a id="page_2-8" class="calibre1"></a>Treatment</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Death is from asphyxiation not exsanguination</b>; maintain gas exchange, reverse coagulopathy and Rx underlying condition; cough suppressant may ↑ risk of asphyxiation</p>
<p class="bl"><span class="sbl">•</span> Inhaled tranexamic acid promising <span class="s">(<i class="calibre3">Chest</i> 2018;154:1379)</span></p>
<p class="bl"><span class="sbl">•</span> Massive hemoptysis: <b class="calibre4">put bleeding side dependent;</b> selectively intubate nl lung if needed</p>
<p class="bl1"><i class="calibre3">Angiography:</i> Dx &amp; Rx (vascular occlusion balloons or <b class="calibre4">selective embol of bronchial art</b>)</p>
<p class="bl1"><i class="calibre3">Rigid bronch:</i> allows more options (electrocautery, laser) than flexible bronch</p>
<p class="bl1"><i class="calibre3">Surgical resection</i></p>
<h2 class="ct"><a id="h27" class="calibre7"></a><a href="part0002.html#rh32" class="calibre7">BRONCHIECTASIS</a></h2>
<p class="h2a">Definition and epidemiology <span class="s">(<i class="calibre3">NEJM</i> 2002;346:1383)</span></p>
<p class="bl"><span class="sbl">•</span> Obstructive airways disease of bronchi and bronchioles, chronic transmural inflammation w/ airway dilatation and thickening, collapsibility, mucus plugging w/ impaired clearance</p>
<p class="h2a">Initial workup</p>
<p class="bl"><span class="sbl">•</span> H&amp;P: cough, dyspnea, copious sputum production, ±hemoptysis, inspiratory “squeaks”</p>
<p class="bl"><span class="sbl">•</span> CXR: scattered or focal; rings of bronchial cuffing; “tram track” of dilated, thick airways</p>
<p class="bl"><span class="sbl">•</span> PFTs: obstructive; chest CT: airway dilation &amp; thickening ± cystic Δs, infiltrates, adenopathy</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre47"/>
<col class="calibre48"/>
<col class="calibre48"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-br"><p class="tabhead">Etiology</p></td>
<td class="bg1-br"><p class="tabhead">Other Features</p></td>
<td class="bg1-b"><p class="tabhead">Diagnostic Testing</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Chronic infxns (eg, MTb, ABPA)</p></td>
<td class="bg0-br"><p class="tab">Chronic cough, freq/persist infiltrate, refract asthma (ABPA)</p></td>
<td class="bg0-b"><p class="tab">Sputum cx (incl mycobact, fungal), ± bronch/BAL, IgE &amp; eos (ABPA)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">1° ciliary dyskin</p></td>
<td class="bg0-br"><p class="tab">Sinusitis, infertility, otitis</p></td>
<td class="bg0-b"><p class="tab">Dynein mutations</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Immunodefic</p></td>
<td class="bg0-br"><p class="tab">Recurrent infxns often as child</p></td>
<td class="bg0-b"><p class="tab">IgA, IgG, IgM, IgG subclasses</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">RA, SLE</p></td>
<td class="bg0-br"><p class="tab">Resp sx may precede joint sx</p></td>
<td class="bg0-b"><p class="tab">RF, ANA</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">IBD</p></td>
<td class="bg0-br"><p class="tab">Not relieved by bowel resection</p></td>
<td class="bg0-b"><p class="tab">Colonoscopy, biopsy</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">α<sub class="calibre13">1</sub>-AT deficiency</p></td>
<td class="bg0-br"><p class="tab">Lower lobe emphysema</p></td>
<td class="bg0-b"><p class="tab">α<sub class="calibre13">1</sub>-AT level</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">Anatomic</p></td>
<td class="bg0-r"><p class="tab">R middle lobe synd. from sharp takeoff, foreign body aspiration</p></td>
<td class="bg"><p class="tab">Bronchoscopy</p></td>
</tr>
</table>
<p class="h2a">Treatment</p>
<p class="bl"><span class="sbl">•</span> Acute exacerbations: antibiotics directed against prior pathogens; if no prior Cx data → FLQ</p>
<p class="bl"><span class="sbl">•</span> Chronic mgmt: treat underlying condition, chest PT, inhaled hypertonic saline, bronchodil.; prophylactic azithro shown to ↓ exacerb in non-CF bronchiectasis <span class="s1r">(<i class="calibre3">JAMA</i> 2013:1251)</span></p>
<p class="h2a">Non-tuberculous mycobacterium <span class="s">(NTM; ubiquitous hydrophilic bacteria)</span></p>
<p class="bl"><span class="sbl">•</span> Chronic cough, ↓ wt; Lady Windermere syndrome: R middle lobe bronchiectasis in elderly ♀ who suppress expectoration</p>
<p class="bl"><span class="sbl">•</span> Dx: CT scan (tree-in-bud, nodules, cavities, bronchiect.), sputum ×3 or BAL, AFB stain + Cx</p>
<p class="bl"><span class="sbl">•</span> Treatment: [azithro or clarithro] + rifamycin &amp; ethambutol for ≥12 mo <span class="s">(<i class="calibre3">Chest</i> 2004;126:566)</span></p>
<h2 class="ct"><a id="h28" class="calibre7"></a><a href="part0002.html#rh33" class="calibre7">CYSTIC FIBROSIS</a></h2>
<p class="h2a">Definition and pathophysiology <span class="s">(<i class="calibre3">NEJM</i> 2015;372:351)</span></p>
<p class="bl"><span class="sbl">•</span> Autosomal recessive genetic disorder due to mutations in chloride channel (CFTR gene)</p>
<p class="bl"><span class="sbl">•</span> ↑ mucus thickness, ↓ mucociliary clearance, ↑ infections → bronchiectasis</p>
<p class="h2a">Clinical features</p>
<p class="bl"><span class="sbl">•</span> Recurrent PNA, sinus infections</p>
<p class="bl"><span class="sbl">•</span> Distal intestinal obstruction syndrome (DIOS), pancreatic insufficiency (steatorrhea, malabsorption, failure to thrive, weight loss), CF-related diabetes, infertility</p>
<p class="h2a">Treatment <span class="s">(<i class="calibre3">Lancet</i> 2016;388:2519)</span></p>
<p class="bl"><span class="sbl">•</span> Acute exacerbations: may be assoc w/ persistent drop in FEV<sub class="calibre8">1</sub> <span class="s1r">(<i class="calibre3">AJRCCM</i> 2010;182:627)</span>; continue aggressive airway clearance, target abx based on sputum cx (incl double coverage for PsA); common pathogens include PsA, <i class="calibre3">S. aureus</i>, non-typeable <i class="calibre3">H flu</i>, <i class="calibre3">Stenotrophomonas</i>, <i class="calibre3">Burkholderia</i>, NTM</p>
<p class="bl"><span class="sbl">•</span> Chronic mgmt: airway clearance with chest PT, inhaled hypertonic saline, inhaled DNAse (dornase alfa), SABA; oral azithromycin if chronic respiratory symptoms, inhaled tobramycin or aztreonam if persistent PsA infection</p>
<p class="bl"><span class="sbl">•</span> CFTR potentiator (ivacaftor) or corrector (lumacaftor, tezacaftor) depending on mutation; combination approved for patients homozygous for ΔF508 (most common mutation) <span class="s1r">(<i class="calibre3">NEJM</i> 2011;365:1663; 2015;373:220; 2017;377:2013 &amp; 2024)</span></p>
<p class="bl"><span class="sbl">•</span> Lung transplantation; refer to lung transplant center when FEV<sub class="calibre8">1</sub> &lt;30% predicted, rapidly declining FEV<sub class="calibre8">1</sub>, 6MWT &lt;400 m, evidence of PHT, significant clinical decline</p>
<h2 class="ct"><a id="h29" class="calibre7"></a><a id="page_2-9" class="calibre7"></a><a href="part0002.html#rh34" class="calibre7">INTERSTITIAL LUNG DISEASE</a></h2>
<p class="h">W<small class="calibre30">ORKUP OF</small> ILD <span class="s1r1">(<i class="calibre3">Thorax</i> 2008;63:v1)</span></p>
<p class="cst"><i class="calibre3">May present as incidental finding, subacute dyspnea, or rapidly progressive hypox. resp fail.</i></p>
<p class="h2a">Broad categories</p>
<p class="bl"><span class="sbl">•</span> (1) <b class="calibre4">Sarcoid;</b> (2) <b class="calibre4">Exposure-related</b> (eg, drugs, XRT, organic &amp; inorganic dusts);</p>
<p class="bl1r"><span class="sbl1r">(3)</span> <b class="calibre4">Collagen vascular dis.</b> (eg, scleroderma, GPA, RA); (4) <b class="calibre4">Idiopathic PNAs</b> (eg, IPF)</p>
<p class="h2a">Rule out mimickers of ILD</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Congestive heart failure</b> (✔ BNP, trial of diuresis); <b class="calibre4">infection:</b> viral, atypical bacterial; <b class="calibre4">malignancy:</b> lymphangitic carcinomatosis, bronchoalveolar, leukemia, lymphoma</p>
<p class="h2a">History and physical exam</p>
<p class="bl"><span class="sbl">•</span> Occupational, exposures (eg, birds), tobacco, meds, XRT, FHx, precipitating event</p>
<p class="bl"><span class="sbl">•</span> Tempo (acute → infxn, CHF, hypersens pneumonitis, eos PNA, AIP, COP, drug-induced)</p>
<p class="bl"><span class="sbl">•</span> Extrapulm signs/sx (skin Δs, arthralgias, arthritis, myalgias, muscle weakness, clubbing)</p>
<p class="h2a">Diagnostic studies (see Appendix &amp; Radiology inserts)</p>
<p class="bl"><span class="sbl">•</span> CXR and <b class="calibre4">high-resolution chest CT</b></p>
<p class="bl1">Upper lobe predom: hypersensitivty pneumonitis, coal, silica, smoking-related ILD</p>
<p class="bl1">Lower lobe predom: IPF, NSIP, asbestosis</p>
<p class="bl1">Adenopathy: malignancy, sarcoidosis, berylliosis, silicosis</p>
<p class="bl1">Pleural disease: collagen-vascular diseases, asbestosis, infections, XRT</p>
<p class="bl"><span class="sbl">•</span> PFTs: ↓ D<sub class="calibre8">L</sub>CO (<i class="calibre3">early sign</i>), restrictive pattern (↓ volumes), ↓ P<sub class="calibre8">a</sub>O<sub class="calibre8">2</sub> (esp. w/ exercise); If restrictive + obstructive, consider sarcoid If combined pulmonary fibrosis and emphysema (CFPE) → near-nl lung vol on PFTs</p>
<p class="bl"><span class="sbl">•</span> Serologies: ✔ ACE, ANA, RF, ANCA, CCP, SSA/SSB, Scl 70, CK, aldolase, myositis panel</p>
<p class="bl"><span class="sbl">•</span> If diffuse alveolar hemorrhage (DAH), Hb typically ↓ 1-2 g/dL</p>
<p class="bl"><span class="sbl">•</span> Bronchoalveolar lavage: dx infxn, hemorrhage, eosinophilic syndromes</p>
<p class="bl"><span class="sbl">•</span> Bx (transbronch, CT-guided, VATS depending on location of findings) if unclear etiology</p>
<p class="h">S<small class="calibre30">PECIFIC</small> E<small class="calibre30">TIOLOGIES</small> <small class="calibre30">OF</small> ILD</p>
<p class="h2a">Sarcoidosis <span class="s">(<i class="calibre3">Lancet</i> 2014;383:1155)</span></p>
<p class="bl"><span class="sbl">•</span> Prevalence: African Americans, northern Europeans, and females; onset in 3<sup class="calibre15">rd</sup>-5<sup class="calibre15">th</sup> decade</p>
<p class="bl"><span class="sbl">•</span> Pathophysiology: depression of cellular immune system peripherally, activation centrally</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre29"/>
<col class="calibre44"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Clinical Manifestations of Sarcoidosis</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Organ System</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Manifestations</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Pulmonary</b></p></td>
<td class="bg0-b"><p class="tab">Hilar LAN; fibrosis; pulm hypertension. Stages: I = bilat hilar</p>
<p class="tab">LAN; II = LAN + ILD; III = ILD only; IV = diffuse fibrosis.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Cutaneous</b> (~15%)</p></td>
<td class="bg0-b"><p class="tab">Waxy skin plaques; lupus pernio (violaceous facial lesions)</p>
<p class="tabh">Erythema nodosum (red tender nodules due to panniculitis, typically on shins). Ddx: idiopathic (34%), infxn (33%, strep, TB), sarcoid (22%), drugs (OCP, PCNs), vasculitis (Behçet’s), IBD, lymphoma.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Ocular</b> (10–30%)</p></td>
<td class="bg0-b"><p class="tab">Anterior &gt; posterior uveitis; ↑ lacrimal gland</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Endo &amp; renal (10%)</p></td>
<td class="bg0-b"><p class="tab">Nephrolithiasis, hypercalcemia (10%), hypercalciuria (40%) Due to vitamin D hydroxylation by macrophages</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Neuro (10% clin, 25% path)</p></td>
<td class="bg0-b"><p class="tab">CN VII palsy, periph neuropathies, CNS lesions, seizures</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Cardiac (5% clin, 25% path)</p></td>
<td class="bg0-b"><p class="tab">Conduction block, VT, CMP</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Liver, spleen, BM</p></td>
<td class="bg0-b"><p class="tab">Granulomatous hepatitis (25%), splenic &amp; BM gran. (50%)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Constitutional</p></td>
<td class="bg0-b"><p class="tab">Fever, night sweats, anorexia &amp; wt loss (a/w hepatic path)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">Musculoskeletal</p></td>
<td class="bg"><p class="tab">Arthralgias, periarticular swelling, bone cysts</p></td>
</tr>
</table>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Löfgren’s syndrome:</i> erythema nodosum + hilar adenopathy + arthritis (good prognosis)</p>
<p class="bl"><span class="sbl">•</span> Diagnostic studies: <b class="calibre4">LN bx</b> → <b class="calibre4">noncaseating granulomas</b> + multinucleated giant cells Endobronchial ultrasonography superior to conventional bronch <span class="s1r">(<i class="calibre3">JAMA</i> 2013;309:2457)</span></p>
<p class="bl1"><sup class="calibre15">1</sup><sup class="calibre15">8</sup>FDG PET can be used to identify extent and potentially targets for dx bx</p>
<p class="bl1">↑ <b class="calibre4">ACE</b> (Se 60%, 90% w/ active dis., Sp 80%, false ⊕ in granulomatous diseases)</p>
<p class="bl"><span class="sbl">•</span> To assess extent: CXR, PFTs, full ophtho exam, ECG, CBC (lymphopenia, ↑ eos), Ca, 24-h urine for Ca, LFTs; ± Holter, echo, cardiac MRI, brain MRI, etc., based on s/s</p>
<p class="bl"><span class="sbl">•</span> Rx: <b class="calibre4">steroids</b> if sx or extrathoracic organ dysfxn (eg, prednisone 20–40 mg/d), improves sx, but doesn’t Δ long-term course; hydroxychloroquine for extensive skin disease; MTX, AZA, mycophenolate, or anti-TNF for chronic/refractory disease</p>
<p class="bl"><span class="sbl">•</span> Prognosis: ~2/3 spontaneously remit w/in 10 y (60–80% of stage I, 50–60% stage II, 30% stage III), w/ relapses uncommon; ~1/3 have progressive disease</p>
<p class="h2a"><a id="page_2-10" class="calibre1"></a>Exposure</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Drugs/Iatrogenic</b></p>
<p class="bl1"><b class="calibre4">Amiodarone:</b> interstitial pneumonitis ↔ org. PNA ↔ ARDS; Rx: d/c amio; steroids</p>
<p class="bl1">Other drugs: nitrofurantoin, sulfonamides, INH, hydralazine</p>
<p class="bl1">Chemo: bleomycin, busulfan, cyclophosphamide, MTX, immunotherapy, XRT</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Pneumoconioses</b> (inorganic dusts) <span class="s1r">(<i class="calibre3">NEJM</i> 2000;342:406; <i class="calibre3">Clin Chest Med</i> 2004;25:467)</span></p>
<p class="bl1">Coal worker’s: upper lobe coal macules; may progress to massive fibrosis</p>
<p class="bl1">Silicosis: upper lobe opacities ± eggshell calcification of lymph nodes; ↑ risk of TB</p>
<p class="bl1">Asbestosis: lower lobe fibrosis, calcified pleural plaques, DOE, dry cough, rales on exam. Asbestos exposure → pleural plaques, benign pleural effusion, diffuse pleural thickening, rounded atelectasis, mesothelioma, lung Ca (esp. in smokers).</p>
<p class="bl1">Berylliosis: multisystemic granulomatous disease that mimics sarcoidosis</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Hypersensitivity pneumonitides</b> (organic dusts): loose, noncaseating <i class="calibre3">granulomas</i></p>
<p class="bl1">Antigens: farmer’s lung (spores of thermophilic actinomyces); pigeon fancier’s lung (proteins from feathers and excreta of birds); humidifier lung (thermophilic bacteria)</p>
<p class="h2a">Collagen vascular diseases <span class="s">(<i class="calibre3">Chest</i> 2013;143:814)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Rheumatologic disease</b></p>
<p class="bl1">Scleroderma: fibrosis in ~50%; PHT seen in ~10% of CREST Pts</p>
<p class="bl1">PM-DM: ILD &amp; skin/muscle findings; MCTD: PHT &amp; fibrosis</p>
<p class="bl1">SLE &amp; RA: pleuritis and pleural effusions more often than ILD; SLE can cause DAH</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Vasculitis</b> (can p/w <i class="calibre3">DAH</i>)</p>
<p class="bl1">Granulomatosis w/ polyangiitis (GPA): ⊕ c-ANCA w/ necrotizing granulomas</p>
<p class="bl1">Eosinophilic GPA (EGPA): ⊕ c- or p-ANCA w/ eosinophilia &amp; necrotizing granulomas</p>
<p class="bl1">Microscopic polyangiitis: ⊕ p-ANCA w/o granulomas</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Goodpasture’s syndrome</b> = DAH + RPGN; typically in smokers; ⊕ anti-GBM in 90%</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Lymphangioleiomyomatosis</b> (LAM): cystic, ↑ in ♀, Rx w/ sirolimus <span class="s1r">(<i class="calibre3">NEJM</i> 2011;364:1595)</span></p>
<p class="h2a">Idiopathic interstitial pneumonias (IIPs) <span class="s">(<i class="calibre3">AJRCCM</i> 2013;188:733)</span></p>
<p class="bl"><span class="sbl">•</span> Definition: <b class="calibre4">ILD of unknown cause;</b> dx by radiographic, histologic, and clinical features</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre41"/>
<col class="calibre28"/>
<col class="calibre33"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabheadc"><b class="calibre4">IIPs</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Type</b></p></td>
<td class="bg0-br"><p class="tab"><b class="calibre4">Imaging/Histology</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Clinical</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">IPF</p></td>
<td class="bg0-br"><p class="tab">UIP pattern: reticular opacities, honeycombing, traction bronchiectasis; peripheral, subpleural, &amp; basal</p></td>
<td class="bg0-b"><p class="tab">Sx &gt;12 mo</p>
<p class="tab">5-y mort ~80%</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">NSIP</p></td>
<td class="bg0-br"><p class="tab">Homogenous ground-glass opacities or consolid., reticular irreg lines; symmetric, peripheral, basal, subpleural. Cellular &amp; fibrotic subtypes, latter similar to UIP.</p></td>
<td class="bg0-b"><p class="tab">Sx mos–y</p>
<p class="tab">5-y mort 10%</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">COP</p></td>
<td class="bg0-br"><p class="tab">Patchy, migratory consolidations; subpleural &amp; peribronchial. Excessive proliferation of granulation tissue in small airways and alveolar ducts.</p></td>
<td class="bg0-b"><p class="tab">Post-infxn, XRT, rxn to drug. 5-y mort &lt;5%</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">AIP</p></td>
<td class="bg0-br"><p class="tab">Diffuse ground-glass opacities, consolidations w/ lobular sparing. Path similar to DAD.</p></td>
<td class="bg0-b"><p class="tab">Sx &lt;3 wk</p>
<p class="tab">6-mo mort 60%</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">DIP</p></td>
<td class="bg0-br"><p class="tab">Diffuse ground-glass opacities, reticular lines; lower zones. Peripheral Mφ in alveoli.</p></td>
<td class="bg" rowspan="2"><p class="tab">30–50 yo <i class="calibre3">smokers</i></p>
<p class="tab">Sx wks–mos</p>
<p class="tab">Death rare</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">RB-ILD</p></td>
<td class="bg0-r"><p class="tab">Bronchial thickening, centrilobular nodules, patchy ground-glass opacities; upper lobe predom. Mφ in alveoli.</p></td>
</tr>
</table>
<p class="tsr">UIP, usual interstitial PNA (IP); IPF, idiopathic pulm fibrosis (<i class="calibre3">Lancet</i> 2017;389:1941 &amp; <i class="calibre3">NEJM</i> 2018;378:1811); NSIP, non-specific IP; COP, cryptogenic organizing PNA; AIP, acute IP (Hamman-Rich syndrome); DIP, desquamative IP; RB-ILD, resp bronchiolitis-assoc ILD.</p>
<p class="bl"><span class="sbl">•</span> Rx for IPF: suppl O<sub class="calibre8">2</sub>, pulm rehab, Rx for GERD, PHT screening, lung tx referral;</p>
<p class="bl1"><b class="calibre4">pirfenidone</b> (antifibrotic) or <b class="calibre4">nintedanib</b> (tyrosine kinase inhib mediating fibrogenic growth factors) ↓ rate of FVC decline <span class="s1r">(<i class="calibre3">NEJM</i> 2014;370:2071 &amp; 2083; <i class="calibre3">AJRCCM</i> 2015;192:3)</span></p>
<p class="bl1">high-dose steroids may be used for acute exacerbations, but no RCT data</p>
<p class="bl"><span class="sbl">•</span> Steroids for other IIPs: NSIP (esp. cellular type) and COP <span class="s1r">(<i class="calibre3">AJRCCM</i> 2000;162:571)</span>; ? benefit for AIP and DIP/RB-ILD (for which Pts should stop smoking)</p>
<p class="h2a">Pulmonary infiltrates w/ eosinophilia (PIE) = eos on BAL ± peripheral blood</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Allergic bronchopulmonary aspergillosis</b> (<b class="calibre4">ABPA</b>)</p>
<p class="bl"><span class="sbl">•</span> Löffler’s syndrome: parasites/drugs → transient pulm infilt + cough, fever, dyspnea, eos</p>
<p class="bl"><span class="sbl">•</span> Acute eosinophilic PNA (AEP): acute hypox febrile illness; Rx: steroids, tobacco cessation</p>
<p class="bl"><span class="sbl">•</span> Chronic eosinophilic pneumonia (CEP): “photonegative” of CHF, typically in women</p>
<p class="h2a">Miscellaneous</p>
<p class="bl"><span class="sbl">•</span> Pulm alveolar proteinosis (PAP): accumulation of surfactant-like phospholipids; white &amp; gummy sputum; BAL milky fluid <span class="s1r">(<i class="calibre3">NEJM</i> 2003;349:2527)</span>; Rx w/ lung lavage &amp; GMCSF</p>
<p class="bl"><span class="sbl">•</span> Langerhans cell granulomatosis (LCG): young ♂ smokers; apical cysts; PTX (25%)</p>
<h2 class="ct"><a id="h30" class="calibre7"></a><a id="page_2-11" class="calibre7"></a><a href="part0002.html#rh35" class="calibre7">PLEURAL EFFUSION</a></h2>
<p class="h2a">Pathophysiology</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Systemic factors</b> (eg, ↑ PCWP, ↓ oncotic pressure) → <i class="calibre3">transudative</i> effusion</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Local factors</b> (ie, Δ pleural surface permeability) → <i class="calibre3">exudative</i> effusion</p>
<p class="h2a">Transudates</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Congestive heart failure</b> (<b class="calibre4">40%</b>): 80% bilateral, ± cardiomegaly on CXR occasionally exudative (especially after aggressive diuresis or if chronic)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Constrictive pericarditis</b> (knock on exam, calcification or thickening on imaging)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Cirrhosis</b> (“hepatic hydrothorax”): diaphragmatic pores allow passage of ascitic fluid often right-sided (<sup class="calibre15">2</sup>/<sub class="calibre8">3</sub>) &amp; massive (even w/o marked ascites)</p>
<p class="bl"><span class="sbl">•</span> Nephrotic syndrome: usually small, bilateral, asymptomatic (r/o PE b/c hypercoag)</p>
<p class="bl"><span class="sbl">•</span> Other: PE (usually exudate), malignancy (lymphatic obstruction), myxedema, CAPD</p>
<p class="h2a">Exudates</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Lung parenchymal infection</b> (<b class="calibre4">25%</b>)</p>
<p class="bl1">Bacterial (parapneumonic): can evolve along spectrum of <i class="calibre3">exudative</i> (but sterile) → <i class="calibre3">fibropurulent</i> (infected fluid) → <i class="calibre3">organization</i> (fibrosis &amp; formation of rigid pleural peel). Common causes: <i class="calibre3">Strep pneumo, Staph aureus, Strep milleri, Klebsiella, Pseudomonas, Haemophilus, Bacteroides, Peptostreptococcus</i>, mixed flora in aspiration pneumonia.</p>
<p class="bl1">Mycobacterial: &gt;50% lymphs 80% of the time, ADA &gt;40, pleural bx ~70% Se</p>
<p class="bl1">Fungal, viral (usually small), parasitic (eg, amebiasis, echinococcosis, paragonimiasis)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Malignancy</b> (<b class="calibre4">15%</b>): primary lung cancer most common, metastases (esp. breast, lymphoma, etc.), mesothelioma (✔ serum osteopontin levels; <i class="calibre3">NEJM</i> 2005;353:15)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Pulmonary embolism</b> (<b class="calibre4">10%</b>): effusions in ~40% of PEs; exudate (75%) &gt; transudate (25%); hemorrhagic—<i class="calibre3">must have high suspicion b/c presentation highly variable</i></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Collagen vascular disease:</b> RA (large), SLE (small), GPA, EGPA</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Abdominal diseases:</b> pancreatitis, cholecystitis, esophageal rupture, abdominal abscess</p>
<p class="bl"><span class="sbl">•</span> Hemothorax (Hct<sub class="calibre8">eff</sub>/Hct<sub class="calibre8">blood</sub> &gt;50%): trauma, PE, malignancy, coagulopathy, leaking aortic aneurysm, aortic dissection, pulmonary vascular malformation</p>
<p class="bl"><span class="sbl">•</span> Chylothorax (triglycerides &gt;110): thoracic duct damage due to trauma, malignancy, LAM</p>
<p class="bl"><span class="sbl">•</span> Other:</p>
<p class="bl1">Post-CABG: left-sided; initially bloody, clears after several wks</p>
<p class="bl1">Dressler’s syndrome (pericarditis &amp; pleuritis post-MI), uremia, post-radiation therapy</p>
<p class="bl1">Asbestos exposure: benign; ⊕ eosinophils</p>
<p class="bl1">Drug-induced (eg, nitrofurantoin, methysergide, bromocriptine, amiodarone): ⊕ eos</p>
<p class="bl1">Uremia; post-XRT; sarcoidosis</p>
<p class="bl1">Meigs’ syndrome: benign ovarian tumor → ascites &amp; pleural effusion</p>
<p class="bl1">Yellow-nail syndrome: yellow nails, lymphedema, pleural effusion, bronchiectasis</p>
<p class="h2a">Diagnostic studies <span class="s">(<i class="calibre3">NEJM</i> 2018;378:740)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Thoracentesis (ideally U/S guided)</b> <span class="s1r">(<i class="calibre3">NEJM</i> 2006;355:e16)</span></p>
<p class="bl1"><i class="calibre3">Indications:</i> <b class="calibre4">all effusions</b> &gt;<b class="calibre4">1 cm in decubitus view</b></p>
<p class="bl2">if suspect due to CHF, can diurese and see if effusions resolve (75% do so in 48 h); <i class="calibre3">asymmetry, fever</i>, <i class="calibre3">chest pain or failure to resolve</i> → thoracentesis</p>
<p class="bl2"><b class="calibre4">parapneumonic effusions should be tapped ASAP</b> <span class="s1r">(<i class="calibre3">cannot</i> exclude infxn clinically)</span></p>
<p class="bl1"><i class="calibre3">Diagnostic studies:</i> ✔ total protein, LDH, glucose, cell count w/ differential, Gram stain &amp; culture, pH; remaining fluid for additional studies as dictated by clinical scenario</p>
<p class="bl1"><i class="calibre3">Complications:</i> PTX (5–10%), hemothorax (~1%), re-expansion pulm edema (if &gt;1.5 L removed), spleen/liver lac.; post-tap CXR not routinely needed <span class="s">(<i class="calibre3">Annals</i> 1996;124:816)</span></p>
<p class="bl1">↓ PTX w/ U/S and experienced supervisor; even with INR ~1.9, risk of bleed low w/ U/S &amp; experienced operator <span class="s1r">(<i class="calibre3">Chest</i> 2009;135:1315 &amp; 2013;144:456; <i class="calibre3">Archives</i> 2010;170:332)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Transudate vs. exudate</b> <span class="s1r">(<i class="calibre3">JAMA</i> 2014;311:2422)</span></p>
<p class="bl1"><b class="calibre4">Light’s criteria:</b> exudate = TP<sub class="calibre8">eff</sub>/TP<sub class="calibre8">serum</sub> &gt;0.5 <i class="calibre3">or</i> LDH<sub class="calibre8">eff</sub>/LDH<sub class="calibre8">serum</sub> &gt;0.6 <i class="calibre3">or</i> LDH<sub class="calibre8">eff</sub> &gt;<sup class="calibre15">2</sup>/<sub class="calibre8">3</sub> ULN of LDH<sub class="calibre8">serum</sub>; 97% Se, 85% Sp; best Se of all methods; however, will misidentify 25% of transudates as exudates; ∴ if clinically suspect transudate but meets criterion for exudate, confirm w/ test w/ higher Sp</p>
<p class="bl1">Exudative criteria w/ better Sp: chol<sub class="calibre8">eff</sub> &gt;55 mg/dL (95–99% Sp); chol<sub class="calibre8">eff</sub> &gt;45 mg/dL <i class="calibre3">and</i> LDH<sub class="calibre8">eff</sub> &gt;200 (98% Sp); chol<sub class="calibre8">eff</sub>/chol<sub class="calibre8">serum</sub> &gt;0.3 (94% Sp); serum-effusion alb gradient ≤1.2 (92% Sp); serum-effusion TP gradient ≤3.1 (91% Sp)</p>
<p class="bl1">CHF effusions: <i class="calibre3">TP may</i> ↑ <i class="calibre3">with diuresis or chronicity</i> → “pseudoexudate”; alb gradient ≤1.2, chol<sub class="calibre8">eff</sub> &gt;60 mg/dL (Se 54%, Sp 92%) or clin judgment to distinguish <span class="s1r">(<i class="calibre3">Chest</i> 2002;122:1524)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Complicated vs. uncomplicated parapneumonic</b> <span class="s1r">(<i class="calibre3">Chest</i> 1995;108:299)</span></p>
<p class="bl1">complicated = ⊕ Gram stain or culture <i class="calibre3">or</i> pH &lt;7.2 <i class="calibre3">or</i> glucose &lt;60</p>
<p class="bl1">complicated parapneumonic effusions usually require tube thoracostomy for resolution</p>
<p class="bl1">empyema = frank pus, also needs tube thoracostomy <span class="s1r">(<i class="calibre3">J Thorac CV Surg</i> 2017;153:e129)</span></p>
<p class="bl"><a id="page_2-12" class="calibre1"></a><span class="sbl">•</span> Additional pleural fluid studies <span class="s1r">(<i class="calibre3">NEJM</i> 2002;346:1971)</span></p>
<p class="bl1">NT-proBNP ≥1500 pg/mL has 91% Se &amp; 93% Sp for CHF <span class="s1r">(<i class="calibre3">Am J Med</i> 2004;116:417)</span></p>
<p class="bl1">WBC &amp; diff.: exudates tend to have ↑ WBC vs. transudates but nonspecific neutrophils → parapneumonic, PE, pancreatitis lymphocytes (&gt;50%) → cancer, TB, rheumatologic eos (&gt;10%) → blood, air, drug rxn, asbestos, paragonimiasis, Churg-Strauss, PE</p>
<p class="bl1">RBC: Hct<sub class="calibre8">eff</sub> 1–20% → cancer, PE, trauma; Hct<sub class="calibre8">eff</sub>/Hct<sub class="calibre8">blood</sub> &gt;50% → hemothorax</p>
<p class="bl1">AFB: yield in TB 0–10% w/ stain, 11–50% w/ culture, ~70% w/ pleural bx</p>
<p class="bl1">adenosine deaminase (ADA): seen w/ granulomas, &gt;70 suggests TB, &lt;40 excludes TB</p>
<p class="bl1">cytology: ideally ≥150 mL and at least 60 mL should be obtained <span class="s1r">(<i class="calibre3">Chest</i> 2010;137:68)</span></p>
<p class="bl1">glucose: &lt;60 mg/dL → malignancy, infection, RA</p>
<p class="bl1">amylase: seen in pancreatic disease and esophageal rupture (salivary amylase)</p>
<p class="bl1">rheumatoid factor, C<sub class="calibre8">H</sub>50, ANA: <i class="calibre3">limited utility</i> in dx collagen vascular disease</p>
<p class="bl1">triglycerides: &gt;110 → chylothorax, 50–110 → ✔ lipoprotein analysis for chylomicrons</p>
<p class="bl1">cholesterol: &gt;60; seen in chronic effusions (eg, CHF, RA, old TB)</p>
<p class="bl1">creatinine: effusion/serum ratio &gt;1 → urinothorax</p>
<p class="bl1">fibulin-3: ↑ plasma and/or effusion levels → mesothelioma <span class="s1r">(<i class="calibre3">NEJM</i> 2012;367:1417)</span></p>
<p class="bl"><span class="sbl">•</span> Chest CT; pleural biopsy; VATS</p>
<p class="bl"><span class="sbl">•</span> Undiagnosed persistent pleural effusions <span class="s1r">(<i class="calibre3">Clin Chest Med</i> 2006;27:309)</span></p>
<p class="bl1"><i class="calibre3">Transudative:</i> most commonly CHF or hepatic hydrothorax. ✔ s/s CHF or cirrhosis, NT-proBNP<sub class="calibre8">eff</sub>; consider intraperitoneal injection of technetium-99m sulfur colloid</p>
<p class="bl1"><i class="calibre3">Exudative</i> (ensure using Sp test listed above): most commonly malig, empyema, TB, PE. ✔ s/s malig, chest CT (I<sup class="calibre15">+</sup>), ADA or IFN-γ release assay; consider thoracoscopy.</p>
<p class="image1"><img src="../images/00041.jpeg" alt="" class="calibre2"/></p>
<p class="h2a">Treatment</p>
<p class="bl"><span class="sbl">•</span> Symptomatic effusion: therapeutic thoracentesis, treat underlying disease process</p>
<p class="bl"><span class="sbl">•</span> Parapneumonic effusion <span class="s1r">(<i class="calibre3">Chest</i> 2000;118:1158)</span></p>
<p class="bl1">uncomplicated → antibiotics for pneumonia</p>
<p class="bl1">&gt;½ <b class="calibre4">hemithorax <i class="calibre3">or</i> complicated <i class="calibre3">or</i> empyema</b> → <b class="calibre4">tube thoracostomy</b> (otherwise risk of organization and subsequent need for surgical decortication)</p>
<p class="bl1">loculated→ tube thoracostomy or VATS; intrapleural t-PA + DNase ↓ need for surgical referral <span class="s1r">(<i class="calibre3">NEJM</i> 2011;365:518)</span></p>
<p class="bl"><span class="sbl">•</span> Malignant effusion: serial thoracenteses vs. tube thoracostomy + pleurodesis (success rate ~80–90%) vs. indwelling pleural catheter, which ↓ hosp days but ↑ adverse events <span class="s1r">(<i class="calibre3">JAMA</i> 2017;318:1903)</span>; systemic steroids &amp; pH &lt;7.2 a/w ↑ pleurodesis failure rate</p>
<p class="bl"><span class="sbl">•</span> TB effusions: effusion will often resolve spontaneously; however, treat Pt for active TB</p>
<p class="bl"><span class="sbl">•</span> Hepatic hydrothorax</p>
<p class="bl1">Rx: Δ pressure gradient (ie, ↓ ascitic fluid volume, NIPPV)</p>
<p class="bl1">avoid chest tubes; prn thoracenteses, pleurodesis, TIPS or VATS closure of diaphragmatic defects if medical Rx fails; NIPPV for acute short-term management</p>
<p class="bl1">spontaneous bacterial empyema (SBEM) can occur (even w/o SBP being present), ∴ thoracentesis if suspect infection</p>
<p class="bl1">transplant is definitive treatment and workup should begin immediately</p>
<h2 class="ct"><a id="h31" class="calibre7"></a><a id="page_2-13" class="calibre7"></a><a href="part0002.html#rh36" class="calibre7">VENOUS THROMBOEMBOLISM (VTE)</a></h2>
<p class="h2a">Definitions</p>
<p class="bl"><span class="sbl">•</span> Superficial thrombophlebitis: pain, tenderness, erythema along superficial vein</p>
<p class="bl"><span class="sbl">•</span> Deep venous thrombosis (DVT): <b class="calibre4"><i class="calibre3">Proximal</i></b> = thrombosis of iliac, femoral, or popliteal veins (nb, “superficial” femoral vein part of deep venous system). <b class="calibre4"><i class="calibre3">Distal</i></b> = calf veins below knee; lower risk of PE/death than proximal <span class="s1r">(<i class="calibre3">Thromb Haem</i> 2009;102:493)</span>.</p>
<p class="bl"><span class="sbl">•</span> Pulmonary embolism (PE): thrombosis originating in venous system and embolizing to pulmonary arterial circulation; 1 case/1000 person y; 250,000/y <span class="s1r">(<i class="calibre3">Archives</i> 2003;163:1711)</span></p>
<p class="h2a">Risk factors</p>
<p class="bl"><span class="sbl">•</span> Virchow’s triad for thrombogenesis</p>
<p class="bl1"><b class="calibre4">stasis:</b> bed rest, inactivity, CHF, CVA w/in 3 mo, air travel &gt;6 h <span class="s1r">(<i class="calibre3">NEJM</i> 2001:779)</span></p>
<p class="bl1"><b class="calibre4">injury to endothelium:</b> trauma, surgery, prior DVT, inflam, central catheter</p>
<p class="bl1"><b class="calibre4">thrombophilia:</b> genetic disorders (qv), HIT, OCP, HRT, tamoxifen, raloxifene</p>
<p class="bl"><span class="sbl">•</span> Malignancy (12% of “idiopathic” DVT/PE; <i class="calibre3">Circ</i> 2013;128:2614)</p>
<p class="bl"><span class="sbl">•</span> History of thrombosis (greater risk of recurrent VTE than genetic thrombophilia)</p>
<p class="bl"><span class="sbl">•</span> Obesity, smoking, acute infection, postpartum <span class="s1r">(<i class="calibre3">JAMA</i> 1997;277:642; <i class="calibre3">Circ</i> 2012;125:2092)</span></p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre17"/>
<col class="calibre24"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Thromboprophylaxis</b> (<span class="tfont1"><i class="calibre3">Chest</i> 2012;141:e195S, 227S, 278S</span>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Patient &amp; Situation</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Prophylaxis</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Low-risk med; same-day surg &amp; &lt;40 y</p></td>
<td class="bg0-b"><p class="tab">Early, aggressive ambulation</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Minor surgery in mobile Pt</p></td>
<td class="bg0-b"><p class="tab">Mechanical Ppx</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">High-risk medical (immobile, h/o VTE, thrombophilia or cancer) &amp; most surgery Pts</p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">UFH</b> 5000 U SC bid/tid, or <b class="calibre4">LMWH</b>, or fonda (if HIT ⊕), or mech Ppx (esp. if high bleed risk); ? extended Ppx w/ DOAC (<span class="tfont"><i class="calibre3">NEJM</i> 2016;375:534</span>). DOAC in ambul. cancer Pts (<span class="tfont"><i class="calibre3">NEJM</i> 2019;380:711 &amp; 720</span>).<a id="st5" class="calibre1"></a><a href="part0007.html#sst5" class="calibre1">*</a></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">High-risk surg. (trauma, stroke, spinal cord injury, h/o VTE/thrombophilia)</p></td>
<td class="bg0-b"><p class="tab">[LMWH or UFH SC] + mech Ppx</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">Orthopedic surgery</p></td>
<td class="bg"><p class="tabh">LMWH [or fonda or warfarin (INR 2–3)] + mech Ppx; DOACs appear favorable vs LMWH</p>
<p class="tabh">After 5 d of DOAC, ASA≈DOAC (<span class="tfont"><i class="calibre3">NEJM</i> 2018;378:699</span>)</p></td>
</tr>
</table>
<p class="tsr">For enox, 30 mg bid for highest risk or 40 mg qd for mod. risk or spinal/epidural anesth. <a id="sst5" class="calibre1"></a><a href="part0007.html#st5" class="calibre1">*</a>If Khorana score ≥2.</p>
<p class="h2a">Clinical manifestations—DVT</p>
<p class="bl"><span class="sbl">•</span> Calf pain, swelling (&gt;3 cm c/w unaffected side), venous distention, erythema, warmth, tenderness, palpable cord, ⊕ Homan’s sign (calf pain on dorsiflexion, seen in &lt;5%)</p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Phlegmasia cerulea dolens:</i> massive prox DVT w/ edema, <i class="calibre3">cyanosis</i>, pain, compart. synd.</p>
<p class="bl"><span class="sbl">•</span> 50% of Pts with sx DVT have asx PE</p>
<p class="bl"><span class="sbl">•</span> Popliteal (Baker’s) cyst: may lead to DVT due to compression of popliteal vein</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre49"/>
<col class="calibre50"/>
<col class="calibre49"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabheadc"><b class="calibre4">“Simplified Wells” Pretest Probability Scoring of DVT</b> (<span class="tfont1"><i class="calibre3">JAMA</i> 2006;295:199</span>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-b" colspan="3"><p class="tabh">+1 point each for: active cancer (Rx ongoing or w/in 6 mo or palliative); paralysis, paresis, or recent immobilization of lower extremities; recently bedridden for ≥3 d or major surgery w/in 12 wk; localized tenderness along distribution of deep venous system; entire leg swelling; calf ≥3 cm larger than asx calf (at 10 cm below tibial tuberosity); pitting edema confined to sx leg; collateral superficial veins (nonvaricose); previous DVT</p>
<p class="tab">–2 points if alternative dx at least as likely as DVT</p></td>
</tr>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabheadc"><b class="calibre4">Pretest Probability Assessment</b> <span class="tfont1">(useful if outPt, less so if inPt; <i class="calibre3">JAMA IM</i> 2015;175:1112</span>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">Score ≤0</p></td>
<td class="bg0-br"><p class="tabc">Score 1 or 2</p></td>
<td class="bg0-b"><p class="tabc">Score ≥3</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tabc">Low probability (5%)</p></td>
<td class="bg0-r"><p class="tabc">Moderate probability (17%)</p></td>
<td class="bg"><p class="tabc">High probability (53%)</p></td>
</tr>
</table>
<p class="bl"><span class="sbl">•</span> For UE DVT, +1 point each for venous cath, local pain, &amp; unilateral edema, –1 if alternative dx. ≤1 = unlikely; ≥2 = likely. U/S if likely or if unlikely but abnl D-dimer <span class="s1r">(<i class="calibre3">Annals</i> 2014;160:451)</span></p>
<p class="h2a">Diagnostic studies—DVT</p>
<p class="bl"><span class="sbl">•</span> D-dimer: &lt;500 helps r/o; ? use 1000 as threshold if low risk <span class="s1r">(<i class="calibre3">Annals</i> 2013;158:93)</span></p>
<p class="bl"><span class="sbl">•</span> Compression U/S &gt;95% Se &amp; Sp for sx DVT (lower if asx); survey whole leg if ≥ mod prob</p>
<p class="capf"><b class="calibre4">Figure 2-3</b> Approach to suspected DVT</p>
<p class="image"><img src="../images/00042.jpeg" alt="" class="calibre2"/></p>
<p class="h2a"><a id="page_2-14" class="calibre1"></a>Clinical manifestations—PE</p>
<p class="bl"><span class="sbl">•</span> Dyspnea (~50%), pleuritic chest pain (~40%), cough (~23%), hemoptysis (~8%)</p>
<p class="bl"><span class="sbl">•</span> ↑ RR (&gt;70%), crackles (51%), ↑ HR (30%), fever, cyanosis, pleural friction rub, loud P<sub class="calibre8">2</sub></p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Massive:</i> syncope, HoTN, PEA; ↑ JVP, R-sided S<sub class="calibre8">3</sub>, Graham Steell (PR) murmur</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre43"/>
<col class="calibre36"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Simplified Wells Pretest Probability Scoring for PE</b> (<span class="tfont1"><i class="calibre3">Annals</i> 2011;154:709)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-b">
<p class="bull-t"><span class="sbull-t">•</span> Prior PE or DVT</p> 
<p class="bull-t"><span class="sbull-t">•</span> Active cancer</p> 
<p class="bull-t"><span class="sbull-t">•</span> Immobilization (bed rest ≥3 d) or surgery w/in 4 wk</p> 
<p class="bull-t"><span class="sbull-t">•</span> Alternative dx less likely than PE</p></td>
<td class="bg0-b">
<p class="bull-t"><span class="sbull-t">•</span> Clinical signs of DVT</p> 
<p class="bull-t"><span class="sbull-t">•</span> HR &gt;100 bpm</p> 
<p class="bull-t"><span class="sbull-t">•</span> Hemoptysis</p></td>
</tr>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Dichotomized Wells Probability Assessment</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">≤1 Variable = “Unlikely” (13% probability)</p></td>
<td class="bg"><p class="tab">≥2 Variables = “Likely” (39% probability)</p></td>
</tr>
</table>
<p class="h2a">Diagnostic studies—PE <span class="s">(<i class="calibre3">EHJ</i> 2014;35:3033)</span></p>
<p class="bl"><span class="sbl">•</span> CXR (limited Se &amp; Sp): 12% nl, atelectasis, effusion, ↑ hemidiaphragm, Hampton hump (wedge-shaped density abutting pleura); Westermark sign (avascularity distal to PE)</p>
<p class="bl"><span class="sbl">•</span> ECG (limited Se &amp; Sp): sinus tachycardia, AF; signs of RV strain → RAD, P pulmonale, RBBB, S<sub class="calibre8">I</sub>Q<sub class="calibre8">III</sub>T<sub class="calibre8">III</sub> &amp; TWI V<sub class="calibre8">1</sub>–V<sub class="calibre8">4</sub> (McGinn-White pattern; <i class="calibre3">Chest</i> 1997;111:537)</p>
<p class="bl"><span class="sbl">•</span> ABG: hypoxemia, hypocapnia, respiratory alkalosis, ↑ A-a gradient <span class="s1r">(<i class="calibre3">Chest</i> 1996;109:78)</span> 18% w/ room air P<sub class="calibre8">a</sub>O<sub class="calibre8">2</sub> 85–105 mmHg, 6% w/ nl A-a gradient <span class="s1r">(<i class="calibre3">Chest</i> 1991;100:598)</span></p>
<p class="bl"><span class="sbl">•</span> D-dimer: high Se, poor Sp (~25%); ELISA has &gt;99% NPV ∴ use to r/o PE if “unlikely” pretest prob <span class="s1r">(<i class="calibre3">JAMA</i> 2006;295:172)</span>; cut-off 500 if &lt;50 y, 10× age if ≥ 50 y <span class="s1r">(<i class="calibre3">JAMA</i> 2014;311:1117)</span></p>
<p class="bl"><span class="sbl">•</span> Echocardiography: useful for risk stratification (RV dysfxn), but not dx (Se &lt;50%)</p>
<p class="bl"><span class="sbl">•</span> V/Q scan: high Se (~98%), low Sp (~10%). Sp improves to 97% for high-prob VQ. Use if pretest prob of PE high and CT not available or contraindicated. Can also exclude PE if low pretest prob, low-prob VQ, but 4% false <span class="s1r">(<i class="calibre3">JAMA</i> 1990;263:2753)</span>.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">CT angiography</b> (CTA; see Radiology inserts; <i class="calibre3">JAMA</i> 2015;314:74): Se ~90% &amp; Sp ~95%; PPV &amp; NPV &gt;95% if imaging concordant w/ clinical suspicion, ≤80% if discordant (∴ need to consider both); ~1/4 of single &amp; subseg may be false ⊕; CT may also provide other dx</p>
<p class="bl"><span class="sbl">•</span> Lower extremity compression U/S shows DVT in ~9%, sparing CTA</p>
<p class="capf"><b class="calibre4">Figure 2-4</b> Approach to suspected PE</p>
<p class="image"><img src="../images/00043.jpeg" alt="" class="calibre2"/></p>
<p class="h2a">Workup for idiopathic VTE <span class="s">(<i class="calibre3">NEJM</i> 2015;373:697)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Thrombophilia workup:</b> ✔ if ⊕ FH, may be helpful but consider timing as thrombus, heparin and warfarin Δ results. Not helpful for Pt if will not Δ management (eg, plan for long-term anticoagulation regardless), although could be of use to relatives.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Malignancy workup:</b> 12% Pts w/ “idiopathic” DVT/PE will have malignancy; age-appropriate screening adequate; avoid extensive w/u</p>
<p class="h2a">Risk stratification for Pts with PE</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">High risk (“massive”):</b> sustained hypotension (SBP &lt;90), bradycardia, or cardiac arrest</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Intermediate risk (“submassive”):</b> evidence of <b class="calibre4">right heart strain</b> w/o hypotension</p>
<p class="bl1">echocardiogram: RV dysfxn (even if normal troponin) <span class="s1r">(<i class="calibre3">Chest</i> 2013;144:1539)</span></p>
<p class="bl1">biomarkers: ↑ troponin, ↑ BNP <span class="s1r">(<i class="calibre3">Chest</i> 2015;147:685)</span></p>
<p class="bl1">CTA: RV/LV dimension ratio &gt;0.9 <span class="s1r">(<i class="calibre3">Circ</i> 2004;110:3276)</span></p>
<p class="bl1">clinical assessment (persistent tachycardia, low BP or hypoxemia) may prompt consideration of advanced Rx (see below)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Low risk:</b> no right heart strain or hypotension</p>
<p class="h2a">Whom to treat <span class="s">(<i class="calibre3">Lancet</i> 2016;388;3060; <i class="calibre3">Chest</i> 2016;149:315; <i class="calibre3">JAMA</i> 2018;320:1583)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Superficial venous thrombosis:</b> elevate extremity, warm compresses, compression stockings, NSAIDs for sx. <i class="calibre3">Anticoag</i> if high risk for DVT (eg, ≥5 cm, proximity to deep vein ≤5 cm, other risk factors) for 4 wk as ~10% have VTE w/in 3 mo <span class="s1r">(<i class="calibre3">Annals</i> 2010;152:218)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">LE DVT:</b> proximal → anticoag; distal → anticoag if severe sx, o/w consider serial imaging over 2 wk and anticoag if extends (although if bleeding risk low, many would anticoag).</p>
<p class="bl"><a id="page_2-15" class="calibre1"></a><span class="sbl">•</span> <b class="calibre4">UE DVT:</b> anticoagulate (same guidelines as LE; <i class="calibre3">NEJM</i> 2011;364:861). If catheter-associated, need not remove if catheter functional and ongoing need for catheter.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">PE:</b> anticoagulate</p>
<p class="h2a">Anticoagulation options <span class="s">(<i class="calibre3">Chest</i> 2016;149:315)</span></p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Initiate parenteral Rx immediately if high or intermed suspicion while dx testing underway</i></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Direct oral anticoag</b> (DOAC; <i class="calibre3">NEJM</i> 2010;363:2499; 2012;366:1287; 2013;369:799 &amp; 1406)</p>
<p class="bl1"><i class="calibre3">preferred</i> b/c as good/better than warfarin in preventing recurrent VTE w/ less bleeding</p>
<p class="bl1">can give as sole anticoag w/ initial loading dose (riva or apixa) or initiate after ≥<i class="calibre3">5 d of parenteral anticoag</i> (edox or dabi; 1<sup class="calibre15">st</sup> dose when d/c IV UFH or w/in 2 h before when next LMWH dose would have been due)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">LMWH</b> (eg, enoxaparin 1 mg/kg SC bid <i class="calibre3">or</i> dalteparin 200 IU/kg SC qd)</p>
<p class="bl1">preferred over UFH (especially in <i class="calibre3">cancer</i>) except: renal failure (CrCl &lt;25), extreme obesity, hemodynamic instability or bleed risk <span class="s1r">(<i class="calibre3">Cochrane</i> 2004;CD001100)</span></p>
<p class="bl1">can use as outPt bridge to long-term oral anticoagulation</p>
<p class="bl"><span class="sbl">•</span> If cancer, LMWH ↓ recurrence and mortality c/w UFH &amp; warfarin <span class="s1r">(<i class="calibre3">Lancet Oncol</i> 2008;9:577)</span>; ✔ head CT for brain mets if melanoma, renal cell, thyroid, chorioCA; edoxaban may be as effective, but ↑ major bleeding, espec in GI malig <span class="s1r">(<i class="calibre3">NEJM</i> 2018;378:615)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Fondaparinux:</b> 5–10 mg SC qd <span class="s1r">(<i class="calibre3">NEJM</i> 2003;349:1695)</span>; use if HIT ⊕; avoid if renal failure</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">IV UFH:</b> 80 U/kg bolus → 18 U/kg/h → titrate to PTT 1.5–2.3 × cntl (eg, 60–85 sec); preferred option when contemplating thrombolysis or catheter-based Rx (qv)</p>
<p class="bl"><span class="sbl">•</span> IV direct thrombin inhibitors (eg, argatroban, bivalirudin) used in HIT ⊕ Pts</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Warfarin</b> (goal INR 2–3): start w/ parenteral anticoag unless instability and ? need for lytic, catheter-based Rx or surg; overlap ≥5 d w/ parenteral anticoag &amp; until INR ≥2 × ≥24 h</p>
<p class="h2a">Systemic thrombolysis <span class="s">(<i class="calibre3">Chest</i> 2012;141:e419S &amp; 2016;149:315)</span></p>
<p class="bl"><span class="sbl">•</span> Typically TPA 100 mg over 2 h or wt-adjusted TNK bolus; risk of ICH ~1.5%, ↑ w/ age</p>
<p class="bl"><span class="sbl">•</span> Consider if low bleed risk w/ acute PE + HoTN or cardiopulm deterioration after anticoag</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">High-risk PE:</b> ↓ death &amp; recurrent PE each by ~50% <span class="s1r">(<i class="calibre3">JAMA</i> 2014;311:2414; <i class="calibre3">EHJ</i> 2015;36:605)</span> &amp; lower PVR long term <span class="s1r">(<i class="calibre3">JACC</i> 1990;15:65)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Intermediate-risk PE:</b> ↓ hemodyn decompensation, ↑ ICH &amp; other major bleeding, ↓ mortality in short term, but no long-term benefit on mortality, PHT or RV fxn; ? consider if &lt;75 y and/or low bleed risk <span class="s1r">(<i class="calibre3">NEJM</i> 2014;370:1402; <i class="calibre3">JAMA</i> 2014;311:2414; <i class="calibre3">JACC</i> 2017;69:1536)</span></p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Half-dose lytic</i> (50 mg or 0.5 mg/kg if &lt;50 kg; 10-mg bolus → remainder over 2 h) in ~intermed. PE: ↓ pulm HTN &amp; ? PE or death w/ ≈ bleeding vs. heparin alone <span class="s1r">(<i class="calibre3">AJC</i> 2013;111:273)</span></p>
<p class="bl"><span class="sbl">•</span> DVT: consider if (a) acute (&lt;14 d) &amp; extensive (eg, iliofemoral), (b) severe sx swelling or ischemia, and (c) low bleed risk</p>
<p class="h2a">Mechanical intervention</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Catheter-directed</b> (fibrinolytic &amp; thrombus fragmentation/aspiration; <i class="calibre3">Circ</i> 2012;126:1917)</p>
<p class="bl1">Consider if PE w/ hemodyn. compromise or high risk &amp; not candidate for systemic lysis or surgical thrombectomy <span class="s1r">(<i class="calibre3">Circ</i> 2011;124:2139)</span>. Preferred to systemic lytic by some centers.</p>
<p class="bl1">U/S-assisted improves hemodynamics &amp; RV fxn vs. anticoag alone <span class="s1r">(<i class="calibre3">EHJ</i> 2015;36:597)</span></p>
<p class="bl1">No benefit in extensive DVT <span class="s1r">(<i class="calibre3">NEJM</i> 2017;377:2240)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Thrombectomy:</b> if large, proximal PE + hemodynamic compromise + contraindic. to lysis; consider in experienced ctr if large prox. PE + RV dysfxn <span class="s1r">(<i class="calibre3">J Thorac CV Surg</i> 2005;129:1018)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">IVC filter:</b> use if anticoag contraindic.; no benefit to adding to anticoag <span class="s1r">(<i class="calibre3">JAMA</i> 2015;313:1627)</span></p>
<p class="bl1">Complications: migration, acute DVT, ↑ risk of recurrent DVT &amp; IVC obstruction (5–18%)</p>
<p class="h2a">Duration of full-intensity anticoagulation</p>
<p class="bl"><span class="sbl">•</span> Superficial venous thrombosis: 4 wk</p>
<p class="bl"><span class="sbl">•</span> 1<sup class="calibre15">st</sup> prox DVT <i class="calibre3">or</i> PE 2° reversible/time-limited risk factor <i class="calibre3">or</i> distal DVT: 3–6 mo</p>
<p class="bl"><span class="sbl">•</span> 1<sup class="calibre15">st</sup> <i class="calibre3">unprovoked</i> prox DVT/PE: ≥3 mo, then reassess; benefit to prolonged Rx Consider clot, bleed risk, Pt preference, and intensity of Rx when crafting strategy</p>
<p class="bl"><span class="sbl">•</span> 2<sup class="calibre15">nd</sup> VTE event or cancer: indefinite (or until cancer cured) <span class="s1r">(<i class="calibre3">NEJM</i> 2003;348:1425)</span></p>
<p class="h2a">Extended antithrombotic strategies</p>
<p class="bl"><span class="sbl">•</span> After ≥6 mo of anticoag, following regimens compared w/ no extended Rx (or ASA):</p>
<p class="bl"><span class="sbl">•</span> Full-dose DOAC: 80–90% ↓ recurrent VTE, 2–5× bleeding, but no signif excess in major bleeding <span class="s1r">(<i class="calibre3">NEJM</i> 2010;363:2499; 2013;368:699 &amp; 709)</span></p>
<p class="bl"><span class="sbl">•</span> ½ dose apixa or riva: ≥75% ↓ recur. VTE, w/o ↑ bleeding <span class="s1r">(<i class="calibre3">NEJM</i> 2013;368:699 &amp; 2017;376:1211)</span></p>
<p class="bl"><span class="sbl">•</span> Warfarin, either regular <span class="s1r">(<i class="calibre3">JAMA</i> 2015;314:31)</span> or low-intensity <span class="s1r">(<i class="calibre3">NEJM</i> 2003;348:1425)</span></p>
<p class="bl"><span class="sbl">•</span> Aspirin: 32% ↓ recurrent VTE <span class="s1r">(<i class="calibre3">NEJM</i> 2012;366:1959 &amp; 367:1979)</span></p>
<p class="h2a">Complications &amp; prognosis</p>
<p class="bl"><span class="sbl">•</span> Postthrombotic syndrome (23–60%): pain, edema, venous ulcers</p>
<p class="bl"><span class="sbl">•</span> Recurrent VTE: 1%/y (after 1<sup class="calibre15">st</sup> VTE) to 5%/y (after recurrent VTE)</p>
<p class="bl"><span class="sbl">•</span> Chronic thromboembolic PHT after acute PE ~2–3%, consider thromboendarterectomy</p>
<p class="bl"><span class="sbl">•</span> Mortality: ~10% for DVT and ~10–15% for PE at 3–6 mo <span class="s1r">(<i class="calibre3">Circ</i> 2008;117:1711)</span></p>
<h2 class="ct"><a id="h32" class="calibre7"></a><a id="page_2-16" class="calibre7"></a><a href="part0002.html#rh37" class="calibre7">PULMONARY HYPERTENSION (PHT)</a></h2>
<p class="cst">PHT defined as PA mean pressure ≥25 mmHg at rest (in future ? ≥20 mmHg based on emerging data <i class="calibre3">[</i> Lancet Respir Med <i class="calibre3">2018;6:168]</i>)<br class="calibre6"/><i class="calibre3">PA mean</i> = <i class="calibre3">CO</i> × <i class="calibre3">PVR</i> + <i class="calibre3">PA wedge pressure. Trans pulm gradient</i> = <i class="calibre3">PA mean – PA wedge.</i></p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre29"/>
<col class="calibre44"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Etiologies (Revised WHO Classification)</b> (<span class="tfont1"><i class="calibre3">JACC</i> 2013;62:D34</span>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Primary pulmonary arterial HTN (PAH)</b> (group 1)</p>
<p class="tab">Precapillary PHT</p>
<p class="tab">PCWP ≤15 mmHg</p>
<p class="tab">↑ transpulm grad</p>
<p class="tab">↑ PVR</p></td>
<td class="bg0-b">
<p class="bull-t"><span class="sbull-t">•</span> Idiopathic (IPAH): yearly incidence 1–2 per million; mean age of onset 36 y (♂ older than ♀); ♂:♀ = ~2:1, usually mild ↑ in PAP</p> 
<p class="bull-t"><span class="sbull-t">•</span> Familial (FPAH)</p> 
<p class="bull-t"><span class="sbull-t">•</span> Associated conditions (APAH)</p> 
<p class="bull-t"><span class="sbull-t">•</span> Connective tissue dis.: CREST, SLE, MCTD, RA, PM, Sjögren</p> 
<p class="bull-t"><span class="sbull-t">•</span> Congenital L→R shunts: ASD, VSD, PDA</p> 
<p class="bull-t"><span class="sbull-t">•</span> Portopulmonary HTN (? 2° vasoactive substances not filtered in ESLD; ≠ hepatopulmonary syndrome)</p> 
<p class="bull-t"><span class="sbull-t">•</span> HIV; drugs &amp; toxins: anorexic agents, SSRIs, <small class="tfont">L</small>-tryptophan</p> 
<p class="bull-t"><span class="sbull-t">•</span> Pulmonary veno-occlusive disease: ? 2° chemo, BMT; orthopnea, pl eff, CHF, nl PCWP; art vasodil. <i class="calibre3">worsen</i> CHF (<span class="tfont"><i class="calibre3">AJRCCM</i> 2000;162:1964</span>)</p> 
<p class="bull-t"><span class="sbull-t">•</span> Pulmonary capillary hemangiomatosis</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Left heart disease</b> (group 2). ↑ PCWP</p></td>
<td class="bg0-b">
<p class="bull-t"><span class="sbull-t">•</span> Left atrial or ventricular (diastolic or systolic) dysfunction</p> 
<p class="bull-t"><span class="sbull-t">•</span> Left-sided valvular heart disease (eg, MS/MR)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Lung diseases and/ or chronic hypoxemia</b> (group 3)</p></td>
<td class="bg0-b"><p class="bull-t"><span class="sbull-t">•</span> COPD<span class="space"></span>• Alveolar hypoventilation (eg, NM disease)</p>
<p class="bull-t"><span class="sbull-t">•</span> ILD <span class="space"></span>    • Chronic hypoxemia (eg, high altitude)</p>
<p class="bull-t"><span class="sbull-t">•</span> Sleep apnea      • Developmental abnormalities</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Chronic thrombo-embolic dis</b> (group 4)</p></td>
<td class="bg0-b">
<p class="bull-t"><span class="sbull-t">•</span> Prox or distal PEs; ~1/2 w/o clinical h/o PE (<span class="tfont"><i class="calibre3">NEJM</i> 2011;364:351</span>)</p> 
<p class="bull-t"><span class="sbull-t">•</span> Nonthrombotic emboli (tumor, foreign body, parasites)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Miscellaneous/ Multifactorial</b> (group 5)</p></td>
<td class="bg">
<p class="bull-t"><span class="sbull-t">•</span> Sarcoidosis, histiocytosis X, LAM, schistosomiasis, ESRD</p> 
<p class="bull-t"><span class="sbull-t">•</span> Compression of pulm vessels (adenopathy, tumor, fibrosing mediastinitis, histoplasmosis, XRT)</p> 
<p class="bull-t"><span class="sbull-t">•</span> Other: thyroid dis., glycogen storage dis., Gaucher dis, HHT, sickle cell etc, chronic myeloprolif d/o, splenectomy</p></td>
</tr>
</table>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> Dyspnea, exertional syncope (hypoxia, ↓ CO), exertional chest pain (RV ischemia)</p>
<p class="bl"><span class="sbl">•</span> Symptoms of R-sided CHF (eg, peripheral edema, RUQ fullness, abdominal distention)</p>
<p class="bl"><span class="sbl">•</span> WHO class: I = asx w/ ordinary activity; II= sx w/ ord. activ; III = sx w/ min activ.; IV = sx at rest</p>
<p class="h2a">Physical exam</p>
<p class="bl"><span class="sbl">•</span> PHT: prominent P<sub class="calibre8">2</sub>, R-sided S<sub class="calibre8">4</sub>, RV heave, PA tap &amp; flow murmur, PR (Graham Steell), TR</p>
<p class="bl"><span class="sbl">•</span> ± RV failure: ↑ JVP, hepatomegaly, peripheral edema</p>
<p class="h2a">Diagnostic studies &amp; workup <span class="s">(<i class="calibre3">JACC</i> 2013;62:D40; <i class="calibre3">Circ</i> 2014;130:1820)</span></p>
<p class="bl"><span class="sbl">•</span> High-res chest CT: dilat. &amp; pruning of pulm arteries, ↑ RA &amp; RV; r/o parenchymal lung dis.</p>
<p class="bl"><span class="sbl">•</span> ECG: RAD, RBBB, RAE (“P pulmonale”), RVH (Se 55%, Sp 70%)</p>
<p class="bl"><span class="sbl">•</span> PFTs: disproportionate ↓ D<sub class="calibre8">L</sub>co, mild restrictive pattern; r/o obstructive &amp; restrictive lung dis.</p>
<p class="bl"><span class="sbl">•</span> ABG &amp; polysomnography: ↓ P<sub class="calibre8">a</sub>O<sub class="calibre8">2</sub> and S<sub class="calibre8">a</sub>O<sub class="calibre8">2</sub> (espec w/ exertion), ↓ P<sub class="calibre8">a</sub>CO<sub class="calibre8">2</sub>, ↑ A-a gradient; r/o hypoventilation and OSA</p>
<p class="bl"><span class="sbl">•</span> TTE: ↑ RVSP (but estimate over/under by ≥10 mmHg in ½ of PHT Pts; <i class="calibre3">Chest</i> 2011;139:988) ↑ RA, RV, &amp; PA; ↑ pressure → interventricular septum systolic flattening (“D” shape) ↓ RV systolic fxn (TAPSE &lt;1.6 cm); TR, PR; r/o LV dysfxn, MV, AoV, congenital disease</p>
<p class="bl"><span class="sbl">•</span> RHC: ↑ RA, RV, &amp; PA pressures; ✔ L-sided pressures and for shunt</p>
<p class="bl1">if PAH: nl PCWP, ↑ transpulmonary gradient (mean PAP-PCWP &gt;12–15), ↑ diastolic pulmonary gradient (PA diastolic – PCWP &gt;7), ↑ PVR, ± ↓ CO</p>
<p class="bl1">if 2° to L-heart disease: PCWP (or LVEDP) &gt;15; if PVR nl → “passive PHT”; PVR &gt;240 suggests mixed picture: if ↓ PCWP → ↓ PVR, then “reactive” PHT; if no Δ, then “fixed”</p>
<p class="bl"><span class="sbl">•</span> CTA (large/med vessel), V/Q scan (small vessel to r/o CTEPH), ± pulm angio if ↑ concern</p>
<p class="bl"><span class="sbl">•</span> Labs: ANA (~40% ⊕ in PAH), RF, anti-Scl-70, anticentromere, ESR; LFTs; HIV</p>
<p class="bl"><span class="sbl">•</span> 6-min walk test (6MWT) or cardiopulmonary exercise testing to establish fxnl capacity</p>
<p class="h2a">Treatment <span class="s">(<i class="calibre3">JACC</i> 2013;62:25S &amp; 2015;65:1976; <i class="calibre3">EHJ</i> 2016;37:67)</span></p>
<p class="bl"><span class="sbl">•</span> Principles: 1) prevent &amp; reverse vasoactive substance imbalance and vascular remodeling</p>
<p class="bl1">2) prevent RV failure: ↓ wall stress (↓ PVR, PAP, RV diam); ensure adeq systemic DBP</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Supportive</b></p>
<p class="bl1">Oxygen: maintain S<sub class="calibre8">a</sub>O<sub class="calibre8">2</sub> &gt;90–92% (reduces vasoconstriction)</p>
<p class="bl1">Diuretics: ↓ RV wall stress and relieve RHF sx; <i class="calibre3">gentle</i> b/c RV is preload dependent</p>
<p class="bl1">Digoxin: control AF, ? counteract neg inotropic effects CCB</p>
<p class="bl1"><a id="page_2-17" class="calibre1"></a>Anticoag: not routinely used; ↓ VTE risk of RHF; ? prevention of <i class="calibre3">in situ</i> microthrombi; ? mortality benefit even if in NSR, no RCTs <span class="s1r">(<i class="calibre3">Chest</i> 2006;130:545)</span></p>
<p class="bl1">Supervised exercise training; aggressive apnea/hypoventilatory Rx w/ CPAP/BiPAP</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Vasodilators</b> (ideally right heart catheterization prior to initiation; <i class="calibre3">NEJM</i> 2004;351:1425) <i class="calibre3">acute vasoreactivity test:</i> use inh NO, adenosine or prostacyclin to identify Pts likely to have long-term response to CCB (⊕ response = ↓ PAP ≥10 mmHg to &lt;40 mmHg w/ ↑ or stable CO); ~10% Pts acute responders; no response → still candidate for other vasodilators</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre51"/>
<col class="calibre52"/>
</colgroup>
<tr class="calibre12">
<td class="bg0-br"><p class="tabhead"><b class="calibre4">Vasoactive Agents</b></p></td>
<td class="bg0-b"><p class="tabhead"><b class="calibre4">Comments</b> <span class="tfont1">(data primarily in Group 1; little evidence in 2° PHT)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">PDE-5 inhibitor</b></p>
<p class="tab">sildenafil, tadalafil, vardenafil</p></td>
<td class="bg0-b"><p class="tab">↑ cGMP → vasodilation, ↓ smooth muscle proliferation, ↓ sx, ↑ 6MWT, no data on clinical outcomes. Often first-line b/c minimal side-effect profile: HA, vision Δ’s, sinus congestion (<span class="tfont"><i class="calibre3">NEJM</i> 2009;361:1864</span>).</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Endothelin receptor antagonists (ERAs)</b> bosentan, ambrisentan, macitentan</p></td>
<td class="bg0-b"><p class="tab">↓ Smooth muscle remodeling, vasodilation, ↓ fibrosis, ↓ sx, ↑ 6MWT, ↓ worsening PAH or need for prostanoids w/ trend for ↓ PAH mort (w/ macitentan). Side effects: ↑ LFTs, HA, anemia, edema, teratogen (<span class="tfont"><i class="calibre3">NEJM</i> 2002;346:896; <i class="calibre3">Circ</i> 2008;117:3010; <i class="calibre3">NEJM</i> 2013;369:809</span>).</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">IV Prostacyclin</b> epoprostenol (Flolan)</p></td>
<td class="bg0-b"><p class="tab">Vasodilation, ↓ plt agg, ↓ smooth muscle proliferation; benefits ↑ w/ time (? vascular remodeling). ↑ 6MWT, ↑ QoL, ↓ <b class="calibre4">mortality.</b> Side effects: HA, flushing, jaw/leg pain, abd cramps, nausea, diarrhea, catheter infxn (<span class="tfont"><i class="calibre3">NEJM</i> 1996;334:296 &amp; 1998;338:273; Annals 2000;132:425</span>).</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Prostacyclin analogues</b> [iloprost (inh) treprostinil (IV, inh, SC)] &amp; <b class="calibre4">receptor agonist</b> selexipag (PO)</p></td>
<td class="bg0-b"><p class="tab">Same mechanism as prostacyclin IV but easier to take, ↓ side effects, and w/o risk of catheter infxn, ↓ sx, ↑ 6MWT; trend to ↓ clinical events w/ iloprost but not treprostinil. Inh Rx with improved V/Q matching. Selexipag ↓ disease prog &amp; hosp by ~40% (<span class="tfont"><i class="calibre3">NEJM</i> 2015;373:2522</span>).</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Soluble guanylate cyclase (sGC) stim</b></p>
<p class="tab">riociguat</p></td>
<td class="bg0-b"><p class="tab">NO-independent ↑ cGMP → vasodilation, ↓ smooth muscle proliferation, ↓ sx, ↑ 6MWT in PAH; ↓ sx, ↓ PVR, ↑ 6MWT in CTEPH (<span class="tfont"><i class="calibre3">NEJM</i> 2013;369:319 &amp; 330</span>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Oral CCB</b></p>
<p class="tab">nifedipine, diltiazem</p></td>
<td class="bg"><p class="tab">Consider if ⊕ acute vasoreactive response; not 1<sup class="calibre35">st</sup> line b/c side effects: HoTN, lower limb edema</p></td>
</tr>
</table>
<p class="bl"><span class="sbl">•</span> Upfront combination Rx (tadalafil + ambrisentan vs. monotherapy): ↓ sx, ↓ NT-BNP, ↑ 6MWT, ↓ hospitalizations <span class="s1r">(<i class="calibre3">NEJM</i> 2015;373:834)</span></p>
<p class="bl"><span class="sbl">•</span> Treat underlying causes of 2° PHT; can use vasodilators, although little evidence</p>
<p class="bl"><span class="sbl">•</span> CTEPH: Rx as above. Pulm endarterectomy potentially curative <span class="s1r">(<i class="calibre3">AJRCCM</i> 2011;183:1605)</span>.</p>
<p class="bl"><span class="sbl">•</span> Refractory PHT: balloon atrial septostomy: R→L shunt causes ↑ CO, ↓ S<sub class="calibre8">a</sub>O<sub class="calibre8">2</sub>, net ↑ tissue O<sub class="calibre8">2</sub> delivery; lung txp (single or bilateral; heart-lung needed if Eisenmenger physiology)</p>
<p class="capf"><b class="calibre4">Figure 2-5</b> Treatment of PAH (modified from <i class="calibre3">JACC</i> 2013;62:D60 &amp; <i class="calibre3">EHJ</i> 2016;37:67)</p>
<p class="image"><img src="../images/00044.jpeg" alt="" class="calibre2"/></p>
<p class="h2a">Management of ICU patient</p>
<p class="bl"><span class="sbl">•</span> Avoid tachyarrhythmias &amp; overly aggressive volume resuscitation</p>
<p class="bl"><span class="sbl">•</span> Caution w/ vasodilators if any L-sided dysfxn. <i class="calibre3">Intubation can cause hemodynamic collapse.</i></p>
<p class="bl"><span class="sbl">•</span> Dobutamine and inhaled NO or prostacyclin</p>
<p class="bl"><span class="sbl">•</span> Consider R-sided mechanical support <span class="s1r">(<i class="calibre3">Circ</i> 2015;132:536)</span></p>
<p class="bl"><span class="sbl">•</span> Consider fibrinolysis if acute, refractory decompensation (eg, TPA 100 mg over 2 h)</p>
<p class="h2a">Prognosis</p>
<p class="bl"><span class="sbl">•</span> Median survival after dx ~2.8 y; PAH (all etiologies): 2-y 66%, 5-y 48% <span class="s1r">(<i class="calibre3">Chest</i> 2004;126:78–S)</span></p>
<p class="bl"><span class="sbl">•</span> Poor prognostic factors: clinical evidence of RV failure, rapidly progressive sx, WHO (modified NYHA) class IV, 6MWT &lt;300 m, peak VO<sub class="calibre8">2</sub> &lt;10.4 mL/kg/min, ↑ RA or RV or RV dysfxn, RA &gt;20 or CI &lt;2.0, ↑ BNP <span class="s1r">(<i class="calibre3">Chest</i> 2006;129:1313)</span></p>
<p class="bl"><span class="sbl">•</span> Lung transplant: 1-y survival 66–75%; 5-y survival 45–55% <span class="s1r">(<i class="calibre3">Chest</i> 2004;126:63S)</span></p>
<h2 class="ct"><a id="h33" class="calibre7"></a><a id="page_2-18" class="calibre7"></a><a href="part0002.html#rh38" class="calibre7">RESPIRATORY FAILURE</a></h2>
<p class="image1"><img src="../images/00045.jpeg" alt="" class="calibre2"/></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">A-a gradient</b> = <b class="calibre4">P<sub class="calibre8">A</sub>O<sub class="calibre8">2</sub> – P<sub class="calibre8">a</sub>O<sub class="calibre8">2</sub>:</b> normal (<i class="calibre3">on room air</i>) = “4 + age/4” or “2.5 + (0.2 × age)”</p>
<p class="bl"><span class="sbl">•</span> Hypoxemia + nl A-a gradient: problem is ↓ P<sub class="calibre8">i</sub>O<sub class="calibre8">2</sub>/F<sub class="calibre8">i</sub>O<sub class="calibre8">2</sub> or ↑ P<sub class="calibre8">a</sub>CO<sub class="calibre8">2</sub> (ie, hypoventilation)</p>
<p class="bl"><span class="sbl">•</span> Hypoxemia + ↑ A-a gradient: problem is either</p>
<p class="bl1">R → L shunt, anatomic (congenital heart dis) or severe pathophys (alveoli filled w/ fluid; eg, PNA, pulm edema); cannot overcome w/ 100% O<sub class="calibre8">2</sub> b/c of sigmoidal Hb-O<sub class="calibre8">2</sub> curve</p>
<p class="bl1">V/Q mismatch where “shunt-like” areas (↓ V &amp; nl Q) cause unoxygenated blood to mix with oxygenated blood; can be overcome w/ ↑ O<sub class="calibre8">2</sub> delivery</p>
<p class="bl1">Diffusion limitation: generally seen with exercise/↑CO</p>
<p class="capf"><b class="calibre4">Figure 2-6</b> Workup of acute hypoxemia</p>
<p class="image"><img src="../images/00046.jpeg" alt="" class="calibre2"/></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Cyanosis:</b> seen when &gt;4 g/dL of reduced Hb in blood vessels of skin/mucous membranes central: ↓ S<sub class="calibre8">a</sub>O<sub class="calibre8">2</sub> (pulm disease, shunt); abnl Hb [metHb, sulfHb, COHb (not true cyanosis)] peripheral: ↓ blood flow → ↑ O<sub class="calibre8">2</sub> extraction (eg, ↓ CO, cold, arterial or venous obstruction)</p>
<p class="imagef"><img src="../images/00047.jpeg" alt="" class="calibre2"/></p>
<p class="fn1">CO binds to Hb more avidly than does O<sub class="calibre13">2</sub>. Pulse oximeter (Ox) misreads COHb as HbO<sub class="calibre13">2</sub> → falsely nl sat.</p>
<p class="fn1">Oxidizing drugs Δ Hb (ferrous) to MetHb (ferric), which cannot carry O<sub class="calibre13">2</sub>. Pulse ox misreads MetHb as HbO<sub class="calibre13">2</sub>.</p>
<p class="fn">Cyanide inhibits mitochondrial O<sub class="calibre13">2</sub> use → cellular hypoxia but pink skin and ↑ <i class="calibre3">venous</i> O<sub class="calibre13">2</sub> sat.</p>
<p class="image1"><img src="../images/00048.jpeg" alt="" class="calibre2"/></p>
<p class="imagef"><img src="../images/00049.jpeg" alt="" class="calibre2"/></p>
<p class="fn">↑ VCO<sub class="calibre13">2</sub> typically transient cause of ↑ P<sub class="calibre13">a</sub>CO<sub class="calibre13">2</sub>; Ddx: exercise, fever, hyperthyroidism, ↑ work of breathing, ↑ carbs.</p>
<h2 class="ct"><a id="h34" class="calibre7"></a><a id="page_2-19" class="calibre7"></a><a href="part0002.html#rh39" class="calibre7">MECHANICAL VENTILATION</a></h2>
<p class="h2a">Indications</p>
<p class="bl"><span class="sbl">•</span> Improve gas exchange: ↑ oxygenation, ↑ alveolar vent and/or reverse acute resp acidosis</p>
<p class="bl"><span class="sbl">•</span> Relieve respiratory distress: ↓ work of breathing (can account for up to 50% of total O<sub class="calibre8">2</sub> consumption), ↓ respiratory muscle fatigue</p>
<p class="bl"><span class="sbl">•</span> Apnea, airway protection, pulmonary toilet</p>
<p class="h">S<small class="calibre30">UPPORTIVE</small> S<small class="calibre30">TRATEGIES</small> P<small class="calibre30">RIOR</small> <small class="calibre30">TO</small> I<small class="calibre30">NTUB</small>. <small class="calibre30">OR</small> A<small class="calibre30">FTER</small> E<small class="calibre30">XTUB</small>.</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre50"/>
<col class="calibre53"/>
<col class="calibre54"/>
</colgroup>
<tr class="calibre12">
<td class="bg1" colspan="3"><p class="tabheadc"><b class="calibre4">Oxygen Delivery Systems</b> (<span class="tfont1"><i class="calibre3">Lancet</i> 2016;387:1867</span>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg3-br"><p class="tab"><b class="calibre4">System or Device</b></p></td>
<td class="bg3-br"><p class="tabheadc"><b class="calibre4">O<sub class="calibre13">2</sub> Flow<sup class="calibre35">a</sup></b></p></td>
<td class="bg3-br"><p class="tab"><b class="calibre4">F<sub class="calibre13">i</sub>O<sub class="calibre13">2</sub> Range &amp; Comments</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg3-br"><p class="tab">Low-flow nasal cannula</p></td>
<td class="bg3-br"><p class="tabheadc">1–6</p></td>
<td class="bg3-br"><p class="tab">24–40%, 1L adds ~3% F<sub class="calibre13">i</sub>O<sub class="calibre13">2</sub></p></td>
</tr>
<tr class="calibre12">
<td class="bg3-br"><p class="tab">Standard face mask</p></td>
<td class="bg3-br"><p class="tabheadc">5–10</p></td>
<td class="bg3-br"><p class="tab">35–50%, minimum 5 L/min</p></td>
</tr>
<tr class="calibre12">
<td class="bg3-br"><p class="tab">Partial rebreather mask</p></td>
<td class="bg3-br"><p class="tabheadc">&gt;10</p></td>
<td class="bg3-br"><p class="tab">40–70%</p></td>
</tr>
<tr class="calibre12">
<td class="bg3-br"><p class="tab">Nonrebreather mask</p></td>
<td class="bg3-br"><p class="tabheadc">&gt;10</p></td>
<td class="bg3-br"><p class="tab">60–80% (not 100% b/c air leaks)</p></td>
</tr>
<tr class="calibre12">
<td class="bg3-br"><p class="tab">Air-entrainment mask</p>
<p class="tab">(Venturi or Venti mask)</p></td>
<td class="bg3-br"><p class="tabheadc">10–15<sup class="calibre35">b</sup></p></td>
<td class="bg3-br"><p class="tab">24–50%, F<sub class="calibre13">i</sub>O<sub class="calibre13">2</sub> stays constant</p></td>
</tr>
<tr class="calibre12">
<td class="bg3-br"><p class="tab">High-flow nasal O<sub class="calibre13">2</sub></p>
<p class="tab">(<span class="tfont"><i class="calibre3">NEJM</i> 2015;372:2185;</span></p>
<p class="tab"><span class="tfont"><i class="calibre3">JAMA</i> 2015;313:2331 &amp; 2016;315:1354)</span></p></td>
<td class="bg3-br"><p class="tabheadc">≤40</p></td>
<td class="bg3-br"><p class="tab">21–100%. In nonhypercapnic acute hypoxemic</p>
<p class="tab">Resp failure, ± ↓ intub. (espec if P<sub class="calibre13">a</sub>O<sub class="calibre13">2</sub>/F<sub class="calibre13">i</sub>O<sub class="calibre13">2</sub> ≤200) &amp; ↓ 90-d mort vs. stnd O<sub class="calibre13">2</sub> or NPPV.</p>
<p class="tab">Routine use after extub. ↓ need for reintub.</p></td>
</tr>
</table>
<p class="tsr"><sup class="calibre14">a</sup>L/min. <sup class="calibre14">b</sup>Total airflow &gt;60L/min. (Adapted from Marino P. <i class="calibre3">The ICU Book</i>, 4th ed, Philadelphia: LWW, 2014:431)</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre29"/>
<col class="calibre44"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Noninvasive Positive Pressure Ventilation (NPPV)</b> <span class="tfont1">(<i class="calibre3">NEJM</i> 2015;372:e30)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Indications</b> (<i class="calibre3">Lancet</i> 2009;374:250)</p></td>
<td class="bg0-b"><p class="tabh"><i class="calibre3">Clinical:</i> mod–severe dyspnea, RR &gt;24–30, signs of ↑ work of breathing, accessory muscle use, abd paradox</p>
<p class="tabh"><i class="calibre3">Gas exchange:</i> P<sub class="calibre13">a</sub>CO<sub class="calibre13">2</sub> &gt;45 mmHg (&amp; significantly worse than baseline), hypoxemia, P<sub class="calibre13">a</sub>O<sub class="calibre13">2</sub>/F<sub class="calibre13">i</sub>O<sub class="calibre13">2</sub> &lt;200</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Contraindications</b></p>
<p class="tab"><span class="tfont"><i class="calibre3">Crit Care Med</i> 2007;35:2402</span></p></td>
<td class="bg0-b"><p class="tabh">Claustrophobia, poor mask fit, Δ<b class="calibre4">MS</b>, vomiting, <b class="calibre4">cannot protect airway</b>, extrapulm organ failure, HD instab, sev UGIB, ↑ secretions</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Continuous positive airway pressure (CPAP)</b></p></td>
<td class="bg0-b"><p class="tabh">≈ PEEP. Pt breathes spont at own rate while vent maintains constant positive airway pressure throughout respiratory cycle.</p>
<p class="tabh">No limit on O<sub class="calibre13">2</sub> delivered (ie, can give hi-flow → F<sub class="calibre13">i</sub>O<sub class="calibre13">2</sub> ≈1.0)</p>
<p class="tabh">Used if primary problem <b class="calibre4"><i class="calibre3">hypoxemia</i></b> (eg, CHF)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Bilevel positive airway pressure (BiPAP)</b></p></td>
<td class="bg0-b"><p class="tabh">≈ PSV + PEEP. Able to set both inspiratory (usually 8–10 cm H<sub class="calibre13">2</sub>O) and expiratory pressures (usually &lt;5 cm H<sub class="calibre13">2</sub>O).</p>
<p class="tabh">Used if primary problem <i class="calibre3">hypoventilation</i>; F<sub class="calibre13">i</sub>O<sub class="calibre13">2</sub> delivery limited</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Mask ventilation</b> (? helmet better; <i class="calibre3">JAMA</i> 2016;315:2435)</p></td>
<td class="bg0-b"><p class="tabh">Tight-fitting mask connecting Pt to a standard ventilator</p>
<p class="tabh">Can receive PS ~20–30 cm H<sub class="calibre13">2</sub>O, PEEP ~10 cm H<sub class="calibre13">2</sub>O, F<sub class="calibre13">i</sub>O<sub class="calibre13">2</sub> ~1.0</p>
<p class="tabh">Used for short-term support (&lt;24 h) for a reversible process</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Conditions w/ strong evidence</b></p>
<p class="tab"><span class="tfont"><i class="calibre3">Lancet</i> 2000;355:1931</span></p>
<p class="tab"><span class="tfont"><i class="calibre3">AJRCCM</i> 2006;173:164</span></p></td>
<td class="bg0-b"><p class="tabh"><b class="calibre4">Cardiogenic pulmonary edema:</b> may ↓ intub. &amp; mortality (<span class="tfont"><i class="calibre3">JAMA</i> 2005;294:3124; <i class="calibre3">Lancet</i> 2006;367:1155</span>) although recent trial (w/ high crossover) did not show any mortality benefit (<i class="calibre3">NEJM</i> 2008;359:142)</p>
<p class="tabh"><b class="calibre4">COPD exac</b> w/ ↑ P<sub class="calibre13">a</sub>CO<sub class="calibre13">2</sub>: ↓ intub. &amp; mort, but if pH &lt;7.3 → intubate</p>
<p class="tabh">High-risk extub. (age &gt;65, CHF, APACHE II &gt;12): NPPV × 24 h directly after extub. → ↓ reintub. and, if P<sub class="calibre13">a</sub>CO<sub class="calibre13">2</sub> &gt;45 mmHg during SBT, ↓ mortality. Does not ∆ total # vent days (<span class="tfont"><i class="calibre3">JAMA</i> 2018;320:1881</span>).</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><span class="tfont"><i class="calibre3">JAMA</i> 2016;315:1345</span></p>
<p class="tab"><span class="tfont"><i class="calibre3">NEJM</i> 2001;344:481</span></p></td>
<td class="bg"><p class="tabh">Hypoxemic resp failure after abdominal surgery: ↓ reintubation</p>
<p class="tabh"><b class="calibre4">Immunosupp</b> w/ infiltrates: ↓ complications &amp; mortality</p></td>
</tr>
</table>
<p class="h">V<small class="calibre30">ENTILATOR</small> M<small class="calibre30">ANAGEMENT</small></p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre29"/>
<col class="calibre44"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Ventilator Modes and Principles</b> (<span class="tfont1"><i class="calibre3">NEJM</i> 2001;344:1986; <i class="calibre3">Chest</i> 2015;148:340</span>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Cont mandatory ventilation (CMV), aka Assist control (AC)</b></p></td>
<td class="bg0-b"><p class="tab">Vent delivers a minimum number of supported breaths</p>
<p class="tab">Additional Pt-initiated breaths trigger <i class="calibre3">fully assisted</i> vent breaths</p>
<p class="tab">∴ Vent-triggered breaths identical to Pt-triggered breaths</p>
<p class="tab">Tachypnea → ? resp. alkalosis, breath-stacking, &amp; auto-PEEP</p>
<p class="tab">May be pressure targeted or volume targeted (qv)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Pressure support vent (PSV)</b></p></td>
<td class="bg0-b"><p class="tab">Support Pt-initiated breaths w/ a set inspiratory pressure &amp; PEEP</p>
<p class="tab">A mode of <i class="calibre3">partial</i> vent support because no set rate</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Other</b></p></td>
<td class="bg"><p class="tabh">Synch intermittent mand. vent: deliver min # supported breaths; V<sub class="calibre13">T</sub> of additional Pt-initiated breaths determined by Pt’s effort</p>
<p class="tabh">Proportional assist ventilation (PAV): delivers variable pressure to achieve targeted % of work of breathing</p></td>
</tr>
</table>
<table class="t-topbot2">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><a id="page_2-20" class="calibre1"></a><p class="tabheadc"><b class="calibre4">Volume or Pressure Targeted</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Volume targeted</b></p></td>
<td class="bg0-b"><p class="tabh">Vent delivers a set V<sub class="calibre13">T</sub>; pressures depend on airway resist. &amp; lung/CW compl.</p>
<p class="tabh"><b class="calibre4">Benefit:</b> ↑ control over ventilation (ideal initial ventilator setting); benefit in ALI/ARDS; easy to measure mechanics (PIP, P<sub class="calibre13">plat</sub>, airway resist., compl.)</p>
<p class="tabh">Volume control (VC) ⊕: vent delivers variable pressure (depending on real- time lung compliance) to achieve set V<sub class="calibre13">T</sub></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Pressure targeted</b></p></td>
<td class="bg0-b"><p class="tabh">Vent delivers a fixed inspiratory pressure regardless of V<sub class="calibre13">T</sub></p>
<p class="tabh">V<sub class="calibre13">T</sub> depends on airway resistance and lung/chest wall compliance</p>
<p class="tabh"><b class="calibre4">Benefit:</b> May ↑ Pt comfort (PSV) requiring less sedation</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">General principles</b></p></td>
<td class="bg"><p class="tabh"><b class="calibre4">Institutional/practitioner preference</b> and <b class="calibre4">Pt comfort</b> usually dictate ventilator strategy; no strategy has proven superior</p>
<p class="tabh"><b class="calibre4">Alarms</b> can be set for ↑ volumes and ↑ airway pressures in pressure- targeted and volume-targeted strategies, respectively</p>
<p class="tabh"><b class="calibre4">Risks:</b> volutrauma (ie, overdistention, if set volume too high; <i class="calibre3">NEJM</i> 2013;369:2126), barotrauma [can happen w/ relatively high set volumes (espec if stiff lungs) or if pressure target set too high; key is to monitor transpulmonary pressure (difference between P<sub class="calibre13">plat</sub> and esophageal ≈ intrapleural), not just airway pressure]; can result in PTX, pneumomediastinum</p>
<p class="tabh"><b class="calibre4">Hypo-/hyperventilation:</b> need to ✔ minute vent &amp; pH/P<sub class="calibre13">a</sub>CO<sub class="calibre13">2</sub></p></td>
</tr>
</table>
<table class="t-topbot2">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Variables on the Ventilator</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">F<sub class="calibre13">i</sub>O<sub class="calibre13">2</sub></b></p></td>
<td class="bg0-b"><p class="tab">Fraction of inspired air that is oxygen</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">V<sub class="calibre13">T</sub></b> (tidal vol)</p></td>
<td class="bg0-b"><p class="tab">Volume of breath delivered; lung-protective ventilation: goal ≤6 ml/kg IBW</p>
<p class="tab">If no ARDS, similar # of vent days at higher V<sub class="calibre13">T</sub> <span class="tfont">(<i class="calibre3">JAMA</i> 2018;320:1872)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">f</b> (resp. rate)</p></td>
<td class="bg0-b"><p class="tab">Rate set by ventilator, f may be lower than RR if Pt triggering breaths.</p>
<p class="tab">Adjust to achieve desired P<sub class="calibre13">a</sub>CO<sub class="calibre13">2</sub>.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Positive end- expiratory pressure (PEEP)</b></p></td>
<td class="bg0-b"><p class="tab">Positive pressure applied during exhalation via resistor in exhalation port</p>
<p class="tabh">Benefits: prevents alveolar collapse, ↓ shunt, ↑ O<sub class="calibre13">2</sub> via alveolar recruitment and improved compliance, allows severely obstructed Pt to initiate breath</p>
<p class="tabh">Cardiac effects: ↓ preload by ↑ intrathoracic pressure → ↓ venous return; ↓ afterload by ↓ cardiac transmural pressure; may ↑ or ↓ CO and may ↑ or ↓ oxygen delivery based on the above</p>
<p class="tabh">Auto-PEEP or intrinsic PEEP: inadequate exhalation time → lungs unable to completely empty before the next breath (ie, “breath stacking”); if flow at end-expiration, there must be pressure = auto-PEEP. Will ↓ preload and may ↓ CO, espec if hypovolemic</p>
<p class="tabh">Will ↑ work of breathing as must be overcome by Pt to trigger breaths; can prevent Pt from triggering ventilator, extrinsic PEEP helps</p>
<p class="tabh">Can be detected if end-expiratory flow ≠ 0 before next breath</p>
<p class="tabh">Can measure by occluding expiratory port of vent at end-expiration</p>
<p class="tabh">Can ↓ by: ↑ exp time, ↓ RR, ↓ V<sub class="calibre13">T</sub>, Rx bronchospasm and secretions</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Inspiratory time</b></p></td>
<td class="bg0-b"><p class="tab">Normally I:E ratio is ~1:2; however, can alter I time (and consequently flow rate, see later); use in pressure-control mode</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Inspiratory flow rates</b></p></td>
<td class="bg0-b"><p class="tab">↑ flow rate → ↓ I time → ↑ E time → ∴ may improve ventilation in obstructive disease, but may affect resp rate and bronchodilation/constriction</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Peak inspiratory pressure (PIP)</b></p></td>
<td class="bg0-b"><p class="tab">Dynamic measurement during inspiration; set in pressure-targeted mode</p>
<p class="tab">Determined by airway resistance and lung/chest wall compliance</p>
<p class="tab">↑ PIP w/o ↑ P<sub class="calibre13">plat</sub> → ↑ airway resist (eg, bronchospasm, plugging)</p>
<p class="tab">↓ PIP → ↓ airway resistance or air leak in the system</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Plateau pressure (P<sub class="calibre13">plat</sub></b>)</p></td>
<td class="bg"><p class="tab">Static measurement at the end of inspiration when there is no flow</p>
<p class="tab">Determined by resp system compliance (resist. not a factor since ∅ flow)</p>
<p class="tabh">↑ P<sub class="calibre13">plat</sub> → ↓ lung or chest wall compliance (eg, PTX, pulmonary edema, pneumonia, atelectasis), ↑ PEEP or auto-PEEP</p>
<p class="tab">P<sub class="calibre13">plat</sub> &lt;30 cm H<sub class="calibre13">2</sub>O ↓ barotrauma (↓ V<sub class="calibre13">T</sub>, ↓ PEEP or ↑ compl [eg, by diuresis])</p></td>
</tr>
</table>
<p class="h2a">Tailoring the ventilator settings</p>
<p class="bl"><span class="sbl">•</span> To improve oxygenation: options include ↑ F<sub class="calibre8">i</sub>O<sub class="calibre8">2</sub>, ↑ PEEP</p>
<p class="bl1">S<sub class="calibre8">a</sub>O<sub class="calibre8">2</sub> 88–92% acceptable <span class="s1r">(<i class="calibre3">AJRCCM</i> 2016;193:43)</span>, do not exceed 96% <span class="s1r">(<i class="calibre3">BMJ</i> 2018;363:k4169)</span></p>
<p class="bl1">First, ↑ F<sub class="calibre8">i</sub>O<sub class="calibre8">2</sub>. If &gt;0.6 and oxygenation remains suboptimal, then try ↑ PEEP:</p>
<p class="bl1">If ↑ P<sub class="calibre8">a</sub>O<sub class="calibre8">2</sub>/F<sub class="calibre8">i</sub>O<sub class="calibre8">2</sub> <i class="calibre3">and</i> P<sub class="calibre8">plat</sub> stable, suggests recruitable lung (ie, atelectasis). If PEEP 20 &amp; F<sub class="calibre8">i</sub>O<sub class="calibre8">2</sub> 1.0 and oxygenation remains suboptimal, consider rescue/expt strategies (see “ARDS”).</p>
<p class="bl1"><a id="page_2-21" class="calibre1"></a>If ↑ PEEP yields no Δ <i class="calibre3">or</i> ↓ P<sub class="calibre8">a</sub>O<sub class="calibre8">2</sub>/F<sub class="calibre8">i</sub>O<sub class="calibre8">2</sub> <i class="calibre3">or</i> ↑ P<sub class="calibre8">a</sub>CO<sub class="calibre8">2</sub>, suggests additional lung <i class="calibre3">not</i> recruitable and instead overdistending lung → ↑ shunt &amp; dead space; ∴ ↓ PEEP</p>
<p class="bl"><span class="sbl">•</span> To improve ventilation: ↑ V<sub class="calibre8">T</sub> or inspiratory pressure, ↑ RR (may need to ↓ I time). Nb, tolerate ↑ P<sub class="calibre8">a</sub>CO<sub class="calibre8">2</sub> (permissive hypercapnia) in ALI/ARDS (qv) as long as pH &gt;7.2.</p>
<p class="h2a">Acute ventilatory deterioration (usually ↑ PIP)</p>
<p class="bl"><span class="sbl">•</span> Response to ↑ PIP: disconnect Pt from vent, bag, auscultate, suction, ✔ CXR &amp; ABG</p>
<p class="capf"><b class="calibre4">Figure 2-7</b> Approach to acute ventilatory deterioration</p>
<p class="center"><img src="../images/00050.jpeg" alt="" class="calibre2"/></p>
<p class="fn">(Adapted from Marino PL. <i class="calibre3">The ICU Book</i>, 4th ed., Philadelphia: LWW, 2014)</p>
<p class="h2a">Liberating from the ventilator <span class="s">(<i class="calibre3">NEJM</i> 2012;367:2233; <i class="calibre3">Lancet</i> 2016;387:1856)</span></p>
<p class="bl"><span class="sbl">•</span> Perform daily assessment of readiness for spontaneous breathing trial (SBT)</p>
<p class="bl"><span class="sbl">•</span> Clinical screening criteria: VS stable, minimal secretions, adequate cough, cause of respiratory failure or previously failed SBT reversed</p>
<p class="bl"><span class="sbl">•</span> Vent parameters: P<sub class="calibre8">a</sub>O<sub class="calibre8">2</sub>/F<sub class="calibre8">i</sub>O<sub class="calibre8">2</sub> &gt;200, PEEP ≤5, f/V<sub class="calibre8">T</sub> &lt;105, V<sub class="calibre8">E</sub> &lt;12 L/min, VC &gt;10 mL/kg; rapid shallow breathing index (f/V<sub class="calibre8">T</sub>) &gt;105 predicts failure, NPV 0.95 <span class="s1r">(<i class="calibre3">NEJM</i> 1991;324:1445)</span></p>
<p class="bl"><span class="sbl">•</span> Daily awakening trial (d/c all sedation; <i class="calibre3">Lancet</i> 2008;371:126): open eyes &amp; w/o: agitation, RR &gt;35, S<sub class="calibre8">a</sub>O<sub class="calibre8">2</sub> &lt;88%, resp distress or arrhythmias (if fail, restart sedation at 1/2 prior dose)</p>
<p class="bl"><span class="sbl">•</span> SBT = CPAP × 30 min superior to T-piece × 120 min <span class="s1r">(<i class="calibre3">JAMA</i> 2019;321:2175)</span></p>
<p class="bl1">failure if: deteriorating ABGs, ↑ RR, ↑ or ↓ HR, ↑ or ↓ BP, diaphoresis, anxiety</p>
<p class="bl"><span class="sbl">•</span> Tolerate SBT → extubation. Fail SBT → ? cause → work to correct → retry SBT qd</p>
<p class="bl"><span class="sbl">•</span> In high-risk Pts, extubation to either NPPV or high-flow O<sub class="calibre8">2</sub> equivalent <span class="s1r">(<i class="calibre3">JAMA</i> 2016;316:1565)</span></p>
<p class="bl"><span class="sbl">•</span> ? acetazolamide in Pts w/ COPD &amp; metabolic alkalosis <span class="s1r">(<i class="calibre3">JAMA</i> 2016;315:480)</span></p>
<p class="h2a">Complications</p>
<p class="bl"><span class="sbl">•</span> Oxygen toxicity (theoretical); proportional to duration + degree of ↑ oxygen (F<sub class="calibre8">i</sub>O<sub class="calibre8">2</sub> &gt;0.6)</p>
<p class="bl"><span class="sbl">•</span> Ventilator-induced lung injury (see “ARDS”)</p>
<p class="bl"><span class="sbl">•</span> Ventilator-associated pneumonia (~1%/d, mortality rate ~30%)</p>
<p class="bl1">typical pathogens: MRSA, <i class="calibre3">Pseudomonas</i>, <i class="calibre3">Acinetobacter</i> and <i class="calibre3">Enterobacter</i> species</p>
<p class="bl1">preventive strategies <span class="s1r">(<i class="calibre3">AJRCCM</i> 2005;171:388)</span>: wash hands, HOB elevated, non-nasal intub., enteral nutrition rather than TPN?, routine suction of subglottic secretions, avoid unnecessary abx &amp; transfusions; routine oral antiseptic controversial</p>
<p class="bl"><span class="sbl">•</span> Stress ulcers/GIB: prophylaxis w/ PPI ↓ GIB, but no Δ in overall course <span class="s1r">(<i class="calibre3">NEJM</i> 2018;379:2199)</span></p>
<p class="bl"><span class="sbl">•</span> Laryngeal</p>
<p class="bl1">edema: for Pts vent &gt;36 h; ? predicted by ⊕ cuff leak test. Methylprednisolone 20 mg IV q4h starting 12 h pre-extub. → ↓↓ edema and 50% ↓ in reintubation <span class="s1r">(<i class="calibre3">Lancet</i> 2007;369:1003)</span>.</p>
<p class="bl1">ulceration: consider <i class="calibre3">tracheostomy</i> for Pts in whom expect &gt;14 d of mech vent → ↓ duration mech vent, ↓ # ICU days <span class="s1r">(<i class="calibre3">BMJ</i> 2005;330:1243)</span>; no benefit to performing at ~1 wk vs. waiting until ~2 wk <span class="s1r">(<i class="calibre3">JAMA</i> 2010;303:1483)</span></p>
<p class="bl"><span class="sbl">•</span> Malnutrition (for all critically ill Pts): <i class="calibre3">enteral nutrition</i> initiated early is safe but not necessary <span class="s1r">(<i class="calibre3">JAMA</i> 2012;307:795)</span>, but bolus may ↑ risk of VAP &amp; <i class="calibre3">C diff.</i> <span class="s1r">(<i class="calibre3">JPEN</i> 2002;26:174)</span>; no clear benefit to ✔ing gastric residuals <span class="s1r">(<i class="calibre3">JAMA</i> 2013;309:249)</span>; permissive enteral underfeeding (~1/2 of calculated caloric req) &amp; standard enteral feeding w/ similar outcomes <span class="s1r">(<i class="calibre3">NEJM</i> 2015;372:2398)</span>; <i class="calibre3">parenteral nutrition</i> should be delayed until after day 8 to ↓ risk of infections, cholestasis, RRT, ventilator days <span class="s1r">(<i class="calibre3">NEJM</i> 2011;365:506)</span></p>
<p class="bl"><span class="sbl">•</span> Oversedation/delirium: BDZs and polypharmacy are risk factors</p>
<p class="bl1">propofol: HoTN in ~25%; <i class="calibre3">propofol infusion syndrome</i> (PRIS) ? espec w/ high (&gt;5 mg/kg/h) &amp; prolonged (&gt;48 h) infusions &amp; concom vasopressors → ↑ AG, cardiac dysfxn, rhabdomyolysis, ↑ triglycerides, &amp; renal failure <span class="s1r">(<i class="calibre3">Crit Care</i> 2009;13:R169)</span></p>
<p class="bl1">dexmedetomidine: no clear benefit on vent-free days <span class="s1r">(<i class="calibre3">JAMA</i> 2016;315:1460 &amp; 2017;317:1321)</span>; dosen't work as sole agent, but spares use of other <span class="s1r">(<i class="calibre3">NEJM</i> 2019;380:2506)</span></p>
<h2 class="ct"><a id="h35" class="calibre7"></a><a id="page_2-22" class="calibre7"></a><a href="part0002.html#rh40" class="calibre7">ACUTE RESPIRATORY DISTRESS SYNDROME</a></h2>
<p class="h2a">Berlin definition <span class="s">(<i class="calibre3">JAMA</i> 2012;307:2526)</span></p>
<p class="bl"><span class="sbl">•</span> Acute onset within 1 week of clinical insult or worsening respiratory status</p>
<p class="bl"><span class="sbl">•</span> Bilateral infiltrates without alternative explanation (eg, effusion, atelectasis, nodules)</p>
<p class="bl"><span class="sbl">•</span> Edema not fully explained by fluid overload or congestive heart failure</p>
<p class="bl"><span class="sbl">•</span> Hypoxemia: P<sub class="calibre8">a</sub>O<sub class="calibre8">2</sub>/F<sub class="calibre8">i</sub>O<sub class="calibre8">2</sub> determined with 5 cm H<sub class="calibre8">2</sub>O of PEEP</p>
<p class="bl1">P<sub class="calibre8">a</sub>O<sub class="calibre8">2</sub>/F<sub class="calibre8">i</sub>O<sub class="calibre8">2</sub> 200–300 = mild ARDS (may be on NPPV), 100–200 = mod, &lt;100 = severe</p>
<p class="h2a">Pathophysiology <span class="s">(<i class="calibre3">Lancet</i> 2016;388:2416)</span></p>
<p class="bl"><span class="sbl">•</span> ↑ intrapulmonary shunt → hypoxemia (∴ Rx w/ PEEP to prevent derecruitment)</p>
<p class="bl"><span class="sbl">•</span> ↑ increased dead space fraction (see Appendix), predicts ↑ mort <span class="s1r">(<i class="calibre3">NEJM</i> 2002;346:1281)</span></p>
<p class="bl"><span class="sbl">•</span> ↓ compliance: V<sub class="calibre8">T</sub>/(P<sub class="calibre8">plat</sub> – PEEP) &lt;50 mL/cm H<sub class="calibre8">2</sub>O</p>
<p class="h2a">Pathology</p>
<p class="bl"><span class="sbl">•</span> Diffuse alveolar damage (DAD) seen in 40% of autopsies <span class="s1r">(<i class="calibre3">AJRCCM</i> 2013;187:761)</span></p>
<p class="bl"><span class="sbl">•</span> If no clear inciting event and ILD considered as alt dx, consider bx <span class="s1r">(<i class="calibre3">Chest</i> 2015;148:1073)</span></p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre26"/>
<col class="calibre26"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Etiologies</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabhead">Direct Injury</p></td>
<td class="bg0-b"><p class="tabhead">Indirect Injury</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r">
<p class="bull-t"><span class="sbull-t">•</span> Pneumonia (~40%) • Inhalation injury</p> 
<p class="bull-t"><span class="sbull-t">•</span> Aspiration (~15%)   • Lung contusion</p> 
<p class="bull-t"><span class="sbull-t">•</span> Near drowning</p></td>
<td class="bg">
<p class="bull-t"><span class="sbull-t">•</span> Sepsis (~25%)  • Pancreatitis</p>
<p class="bull-t"><span class="sbull-t">•</span> Shock<span class="space"></span>• Trauma/multiple fractures</p>
<p class="bull-t"><span class="sbull-t">•</span> DIC<span class="space"></span>    • Transfusion (TRALI)</p></td>
</tr>
</table>
<p class="h2a">Treatment <span class="s">(<i class="calibre3">NEJM</i> 2017;377:562; <i class="calibre3">ARJCCM</i> 2017;195:1253; <i class="calibre3">JAMA</i> 2018;319:698)</span></p>
<p class="bl"><span class="sbl">•</span> Goal is to maintain gas exchange, sustain life, &amp; avoid ventilator-induced lung injury (VILI)</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre27"/>
<col class="calibre28"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-br"><p class="tabhead"><b class="calibre4">Mechanisms of VILI</b></p></td>
<td class="bg1-b"><p class="tabheadc">Ventilator Strategies (see <a href="http://ARDSnet.org" class="calibre1">ARDSnet.org</a>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Barotrauma/volutrauma:</b> alveolar dist → mech damage</p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">V<sub class="calibre13">T</sub></b> ≤<b class="calibre4">6 mL/kg, P<sub class="calibre13">plat</sub></b> ≤<b class="calibre4">30 cm H<sub class="calibre13">2</sub>O</b>, tolerate ↑ P<sub class="calibre13">a</sub>CO<sub class="calibre13">2</sub> (but keep pH &gt;7.2), ↓ mortality (<span class="tfont"><i class="calibre3">NEJM</i> 2000;342:1301</span>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Biotrauma</b> → SIRS</p></td>
<td class="bg0-b"><p class="tab">Low V<sub class="calibre13">T</sub>, open lung strategy w/ high PEEP</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Atelectrauma:</b> repetitive alveoli recruit &amp; decruit</p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Titrate PEEP to prevent tidal alveolar collapse</b></p>
<p class="tab">See below for options</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Hyperoxia:</b> ? injury; worsened V/Q matching</p></td>
<td class="bg"><p class="tab">↑ <b class="calibre4">PEEP</b> rather than F<sub class="calibre13">i</sub>O<sub class="calibre13">2</sub> (keep &lt;0.60)</p>
<p class="tab">O<sub class="calibre13">2</sub>-induced injury only theoretical in humans</p></td>
</tr>
</table>
<p class="h2a">The 6 Ps</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">PEEP</b> (see below)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Proning:</b> if P<sub class="calibre8">a</sub>O<sub class="calibre8">2</sub>/F<sub class="calibre8">i</sub>O<sub class="calibre8">2</sub> &lt;150, prone positioning ≥16 h ↓ mort ~50% <span class="s1r">(<i class="calibre3">NEJM</i> 2013;368:2159)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Paralysis:</b> no benefit routinely <span class="s1r">(<i class="calibre3">NEJM</i> 2019;380:1997)</span>; consider if Pt-vent dyssynchrony</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Peeing (fluid balance):</b> target CVP 4–6 cm H<sub class="calibre8">2</sub>O (if nonoliguric &amp; normotensive) → ↑ vent/ICU-free days, but no Δ mortality <span class="s1r">(<i class="calibre3">NEJM</i> 2006;354:2564)</span>; PA catheter unproven <span class="s1r">(<i class="calibre3">NEJM</i> 2006;354:2213)</span>; consider BNP &gt;200 to trigger diuresis (UOP goal 4.5–9 mL/kg/h × 3 h)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Pulm vasodilators:</b> inhaled NO or prostacyclins ↑ P<sub class="calibre8">a</sub>O<sub class="calibre8">2</sub>/F<sub class="calibre8">i</sub>O<sub class="calibre8">2;</sub> no ↓ mort or vent-free days <span class="s1r">(<i class="calibre3">BMJ</i> 2007;334:779)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Perfusion (V-V ECMO):</b> may be useful if refractory <span class="s1r">(<i class="calibre3">NEJM</i> 2011;365:1905 &amp; 2018;378:1965)</span></p>
<p class="h2a">PEEP titration methods <span class="s">(best method unclear)</span></p>
<p class="bl"><span class="sbl">•</span> No benefit at given V<sub class="calibre8">T</sub> if titrated to P<sub class="calibre8">a</sub>O<sub class="calibre8">2</sub> alone <span class="s1r">(<i class="calibre3">NEJM</i> 2004;351:327; <i class="calibre3">JAMA</i> 2008;299:637)</span></p>
<p class="bl"><span class="sbl">•</span> Best PEEP trial: incremental PEEP titration using compliance, O<sub class="calibre8">2</sub>, hemodynamics</p>
<p class="bl1">If able to ↑ PEEP w/o ↑ P<sub class="calibre8">plat</sub>, suggests “recruitability”</p>
<p class="bl1">∴↑ PEEP if → ↑ S<sub class="calibre8">a</sub>O<sub class="calibre8">2</sub> (target ≥88–90%) &amp; P<sub class="calibre8">plat</sub> ≤30 cm H<sub class="calibre8">2</sub>O → ↓ time on vent, better lung mechanics <span class="s1r">(<i class="calibre3">JAMA</i> 2008;299:646)</span>, ? ↓ mortality <span class="s1r">(<i class="calibre3">JAMA</i> 2010;303:865)</span></p>
<p class="bl"><span class="sbl">•</span> ARDSnet “high” PEEP table for optimal F<sub class="calibre8">i</sub>O<sub class="calibre8">2</sub>/PEEP combo for goal S<sub class="calibre8">a</sub>O<sub class="calibre8">2</sub> (<a href="http://ARDSnet.org" class="calibre1">ARDSnet.org</a>)</p>
<p class="bl"><span class="sbl">•</span> Recruitment maneuvers: stepwise preferred over sustained inflation, evidence insufficient to recommend routine use <span class="s1r">(<i class="calibre3">Resp Care</i> 2015;60:1688)</span>; recruitment maneuvers at high pressures ? ↑ mortality <span class="s1r">(<i class="calibre3">JAMA</i> 2017;318:1335)</span></p>
<p class="bl"><span class="sbl">•</span> Esophageal balloon: used to estimate pleural pressure and thereby estimate trans-pulmonary pressure (ie, true airway distending pressure). Adjusting PEEP according to esoph pressure to maintain optimal transpulm. pressure does not Δ ventilator-free days or mortality, although does ↓ need for advanced rescue Rx (see above) <span class="s1r">(<i class="calibre3">JAMA</i> 2019;321:846)</span>.</p>
<p class="bl"><span class="sbl">•</span> Driving pressure (ΔP = P<sub class="calibre8">plateau</sub>–PEEP): ↓ ΔP a/w ↑ survival; target &lt;15 <span class="s1r">(<i class="calibre3">NEJM</i> 2015;372:747)</span></p>
<p class="h2a">Prognosis <span class="s">(<i class="calibre3">JAMA</i> 2016;315:788)</span></p>
<p class="bl"><span class="sbl">•</span> Mortality ~40% overall in clinical trials; 9–15% resp. causes, 85–91% extrapulm (MODS)</p>
<p class="bl"><span class="sbl">•</span> Survivors: PFTs ~normal, ↓ D<sub class="calibre8">L</sub>CO, muscle wasting, weakness persists <span class="s1r">(<i class="calibre3">NEJM</i> 2003;348:683)</span>, ↓ exercise tolerance, ↓ QoL, ↑ psych morbidity <span class="s1r">(<i class="calibre3">NEJM</i> 2011;364:1293)</span>; 44% of previously employed Pts jobless at 12 mos <span class="s1r">(<i class="calibre3">AJRCCM</i> 2017;196:1012)</span></p>
<h2 class="ct"><a id="h36" class="calibre7"></a><a id="page_2-23" class="calibre7"></a><a href="part0002.html#rh41" class="calibre7">SEPSIS AND SHOCK</a></h2>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre55"/>
<col class="calibre56"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Definitions</b> <span class="tfont1">(<i class="calibre3">JAMA</i> 2016;315:801; 2017;317:290 &amp; 301)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Sepsis</b></p></td>
<td class="bg0-b"><p class="tab">Life-threatening organ dysfxn (SOFA Δ ≥2) due to infection</p>
<p class="tab">Quick SOFA (qSOFA): ≥2 of the following: RR ≥22, ΔMS, SBP ≤100 mmHg</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Septic shock</b></p></td>
<td class="bg0-b"><p class="tab">Sepsis-induced circulatory and cellular/metabolic abnormalities severe enough to ↑ mortality; hypotension requiring pressors for MAP ≥65 and lactate &gt;2 despite adequate fluid resuscitation</p></td>
</tr>
<tr class="calibre12">
<td class="bg" colspan="2">
<p class="tab"><b class="calibre4">Sequential Organ Failure Assessment (SOFA):</b> ↑ points for worsening organ dysfxn: respiration (↓ P:F ratio); coag (↓ plt); liver (↑ bili); CV (↓ MAP or ↑ pressors); CNS (↓ GCS); renal (↑ Cr or ↓ UOP)</p></td>
</tr>
</table>
<p class="fn"><b class="calibre4">Systemic inflammatory response syndrome (SIRS):</b> ≥2 of the following: (1) Temp &gt;38 or &lt;36°C, (2) HR &gt;90, (3) RR &gt;20 or PaCO<sub class="calibre13">2</sub> &lt;32, (4) WBC &gt;12k or &lt;4k or &gt;10% bands. No longer used.</p>
<p class="h2a"><b class="calibre4">Shock</b> <span class="s">(see “PA Catheter &amp; Tailored Therapy” for subtypes; <i class="calibre3">NEJM</i> 2013;369:1726)</span></p>
<p class="bl"><span class="sbl">•</span> Tissue hypoxia due to ↓ tissue perfusion and hence ↓ tissue O<sub class="calibre8">2</sub> delivery and/or ↑ O<sub class="calibre8">2</sub> consumption or inadequate O<sub class="calibre8">2</sub> utilization</p>
<p class="bl"><span class="sbl">•</span> Typical signs include HoTN (SBP &lt;90 mmHg or drop in SBP &gt;40 mmHg), tachycardia, oliguria (UOP &lt;0.5 cc/kg/h), Δ mentation, metabolic acidosis ± ↑ lactate</p>
<p class="bl"><span class="sbl">•</span> Hard to dx as ↑ SVR can maintain SBP, but tissue perfusion poor; shock index (HR/SBP) &gt;0.9 and pulse pressure [(SBP – DBP)/SBP] &lt;25% clues to significant shock</p>
<p class="h">M<small class="calibre30">ANAGEMENT</small></p>
<p class="h2a"><b class="calibre4">Fluids</b></p>
<p class="bl"><span class="sbl">•</span> Aggressive IV fluid resuscitation (30 mL/kg) admin in boluses w/in 3 h of presentation</p>
<p class="bl"><span class="sbl">•</span> Crystalloid as good as colloid for resuscitation <span class="s1r">(<i class="calibre3">JAMA</i> 2013;310:1809; <i class="calibre3">NEJM</i> 2014;370:1412)</span></p>
<p class="bl"><span class="sbl">•</span> Balanced crystalloid (LR, Plasma-Lyte) ↓ rate of major kidney events (composite of death, need for RRT, or persistent renal dysfxn) compared w/ NS <span class="s1r">(<i class="calibre3">NEJM</i> 2018;378:829)</span></p>
<p class="bl"><span class="sbl">•</span> NaHCO<sub class="calibre8">3</sub> may ↓ mortality &amp; need for RRT if AKI &amp; pH &lt;7.2 <span class="s1r">(<i class="calibre3">Lancet</i> 2018;392:31)</span></p>
<p class="bl"><span class="sbl">•</span> Predictors of fluid responsiveness: pulse pressure variation &gt;13% w/ respiration <span class="s1r">(<i class="calibre3">Chest</i> 2008;133:252)</span>; resp. variation in IVC diam, or &gt;10% ↑ in pulse pressure w/ passive leg raise. Static CVP poor surrogate.</p>
<p class="bl"><span class="sbl">•</span> After early resuscitation, if ALI/ARDS, target CVP 4–6 mmHg because additional fluids may be harmful → ↑ ventilator/ICU days <span class="s1r">(<i class="calibre3">NEJM</i> 2006;354:2564; <i class="calibre3">Chest</i> 2008;133:252)</span></p>
<p class="h2a"><b class="calibre4">Pressors &amp; inotropes</b> <span class="s">(also see “ICU Medications”)</span></p>
<p class="bl"><span class="sbl">•</span> MAP target 65–70 mmHg as good as 80–85 and ↓ AF <span class="s1r">(<i class="calibre3">NEJM</i> 2014;370:1583)</span></p>
<p class="bl"><span class="sbl">•</span> Norepinephrine: ↓ arrhythmia &amp; mortality c/w dopamine <span class="s1r">(<i class="calibre3">NEJM</i> 2010;362:779; <i class="calibre3">Crit Care Med</i> 2012;40:725)</span> and ∴ is pressor of choice in septic shock</p>
<p class="bl"><span class="sbl">•</span> Vasopressin: adding to norepi (vs. using high-dose norepi) ↓ risk of AF &amp; RRT by ~¼ <span class="s1r">(<i class="calibre3">JAMA</i> 2018;319:1889)</span></p>
<p class="bl"><span class="sbl">•</span> If targets (see below) not reached after adequate fluids and pressors, consider inotropes</p>
<p class="h2a"><b class="calibre4">Targets</b></p>
<p class="bl"><span class="sbl">•</span> Lactate clearance (≥20%/2 h) as effective as S<sub class="calibre8">cv</sub>O<sub class="calibre8">2</sub> to guide resusc. <span class="s1r">(<i class="calibre3">JAMA</i> 2010;303:739)</span></p>
<p class="bl"><span class="sbl">•</span> Targeting capillary refill time ≤3 sec (check q30min) as good if not better than lactate clearance <span class="s1r">(<i class="calibre3">JAMA</i> 2019;321:654)</span></p>
<p class="h2a"><b class="calibre4">Antibiotics</b></p>
<p class="bl"><span class="sbl">•</span> Start empiric IV abx as soon as possible following recognition of severe sepsis or septic shock; every hr delay in abx admin a/w 7.6% ↑ in mortality <span class="s1r">(<i class="calibre3">Crit Care Med</i> 2006;34:1589)</span>, abx admin w/in 3 h of presentation in the ED a/w ↓ in-hospital mortality <span class="s1r">(<i class="calibre3">NEJM</i> 2017;376:2235)</span></p>
<p class="bl"><span class="sbl">•</span> If possible, obtain 2 sets of BCx before urgently starting abx (but do not delay abx)</p>
<p class="bl"><span class="sbl">•</span> Broad gram-positive (incl MRSA) &amp; gram-neg (incl highly resistant) coverage, ± anaerobes</p>
<p class="bl"><span class="sbl">•</span> Procalcitonin-guided <i class="calibre3">cessation</i> (not initiation) ↓ mortality <span class="s1r">(<i class="calibre3">Crit Care Med</i> 2018;46:684)</span></p>
<p class="bl"><span class="sbl">•</span> Empiric micafungin in critically ill Pts w/ Candida colonization &amp; sepsis of unknown etiology ↓ invasive fungal infxns &amp; tended ↑ invasive fungal infxn-free survival, espec. in Pts w/ 1,3-b-D-glucan &gt;80 <span class="s1r">(<i class="calibre3">JAMA</i> 2016;316:1555)</span></p>
<p class="h2a"><b class="calibre4">Steroids</b> <span class="s">(<i class="calibre3">Crit Care Med</i> 2018;46:1411)</span></p>
<p class="bl"><span class="sbl">•</span> Hydrocortisone 50 mg IV q6 + fludrocortisone 50 µg via NGT daily in septic shock ↓ duration of shock and may ↓ mortality <span class="s1r">(<i class="calibre3">NEJM</i> 2018; 378:797 &amp; 809)</span></p>
<p class="bl"><span class="sbl">•</span> Consider in Pts w/ refractory shock on escalating doses of pressors</p>
<p class="h2a"><b class="calibre4">Early Goal-Directed Therapy (EGDT)</b></p>
<p class="bl"><span class="sbl">•</span> Historically: IVF &amp; pressors for MAP ≥65 mmHg, CVP 8–12 mmHg, UOP ≥0.5 mL/kg/h; inotropes &amp; PRBCs for S<sub class="calibre8">cv</sub>O<sub class="calibre8">2</sub> ≥70% in 6 h <span class="s1r">(<i class="calibre3">NEJM</i> 2001;345:1368)</span></p>
<p class="bl"><span class="sbl">•</span> However, now in era of early abx and adequate fluid resuscitation, no ↓ in mortality w/ EGDT vs. current usual care, and ↑ hospital costs <span class="s1r">(<i class="calibre3">NEJM</i> 2017; 376:2223)</span></p>
<h2 class="ct"><a id="h37" class="calibre7"></a><a id="page_2-24" class="calibre7"></a><a href="part0002.html#rh42" class="calibre7">TOXICOLOGY</a></h2>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre45"/>
<col class="calibre46"/>
<col class="calibre46"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b"><p class="tabhead">Drug/Toxin</p></td>
<td class="bg1-b"><p class="tabhead">Signs/Sx and Diagnostics</p></td>
<td class="bg1-b"><p class="tabhead">Management Options</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Acetaminophen</b></p></td>
<td class="bg0-br"><p class="tab">Vomiting, ↑ AG &amp; nl OG metabolic acidosis, hepatitis &amp; hepatic failure, renal failure</p></td>
<td class="bg0-b"><p class="tab">N-acetylcysteine (NAC) infusion</p>
<p class="tab">Hemodialysis if massive O/D</p>
<p class="tab">See “Acute liver failure”</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Salicylates</b></p></td>
<td class="bg0-br"><p class="tab">Tinnitus, hyperventilation, abd. pain, vomiting, ΔMS,</p>
<p class="tab">mixed ↑ AG &amp; nl OG metabolic acidosis + respiratory alkalosis</p></td>
<td class="bg0-b"><p class="tab">IVF resuscitation</p>
<p class="tab">Alkalinization w/ NaHCO<sub class="calibre13">3</sub></p>
<p class="tab">Maintain respiratory alkalemia</p>
<p class="tab">Consider hemodialysis</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Opioids</b></p></td>
<td class="bg0-br"><p class="tab">↓ mentation, ↓ RR, miosis</p></td>
<td class="bg0-b"><p class="tab">IV naloxone</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Benzodiazepines</b></p></td>
<td class="bg0-br"><p class="tab">↓ mentation, ataxia, ↓ RR</p></td>
<td class="bg0-b"><p class="tab">Flumazenil <i class="calibre3">not</i> rec (can precipitate withdrawal/seizures)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Calcium channel blockers</b></p></td>
<td class="bg0-br"><p class="tabh">Bradycardia, AV block, hypotension, HF, hyperglycemia</p></td>
<td class="bg0-b"><p class="tab">IVF, vasopressors, Ca infusion, hyperinsulinemic euglycemia,</p>
<p class="tab">? intralipid emulsion, pacing</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Beta blockers</b></p></td>
<td class="bg0-br"><p class="tab">Bradycardia, AV block, hypotension, HF, hypoglycemia</p></td>
<td class="bg0-b"><p class="tab">Glucagon, vasopressors, pacing</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Digoxin</b></p></td>
<td class="bg0-br"><p class="tabh">N/V, bradycardia, AV block, delirium, xanthopsia</p>
<p class="tab">✔ serum dig level (but may be inaccurate if &lt;6 h since last dose), renal function</p></td>
<td class="bg0-b"><p class="tab">Correct hypokalemia</p>
<p class="tab">Digibind if hyperkalemia, life-threatening dysrhythmia</p>
<p class="tab">Consider hemodialysis</p>
<p class="tab">Lidocaine for arrhythmias</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Tricyclic antidepressants</b></p></td>
<td class="bg0-br"><p class="tab">Hypotension, seizures, arrhythmia, ↑ QRS, ↑ QT</p></td>
<td class="bg0-b"><p class="tab">IVF resuscitation, IV sodium bicarbonate, vasopressors</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Lithium</b></p></td>
<td class="bg0-br"><p class="tab">N/V/D, tremor, hyperreflexia, clonus, drowsiness, seizure, ↑ QT, AV block, bradycardia</p></td>
<td class="bg0-b"><p class="tab">IVF (NS), maintain UOP</p>
<p class="tab">Consider hemodialysis</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Ethylene glycol</b></p></td>
<td class="bg0-br"><p class="tab">CNS depression, ↑ AG &amp; OG metabolic acidosis</p></td>
<td class="bg0-b"><p class="tab">Ethanol or fomepizole, NaHCO<sub class="calibre13">3</sub></p>
<p class="tab">Consider hemodialysis</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Methanol</b> (<i class="calibre3">NEJM</i> 2018;378:270)</p></td>
<td class="bg0-br"><p class="tab">CNS depression, blindness</p>
<p class="tab">↑ AG &amp; OG met. acidosis</p></td>
<td class="bg0-b"><p class="tab">Ethanol or fomepizole, NaHCO<sub class="calibre13">3</sub></p>
<p class="tab">Consider hemodialysis</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Isopropanol</b></p></td>
<td class="bg0-br"><p class="tab">CNS depression, gastritis</p></td>
<td class="bg0-b"><p class="tab">Supportive care</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Carbon monoxide</b></p></td>
<td class="bg0-br"><p class="tab">HA, dizziness, nausea, ΔMS</p>
<p class="tab">carboxyHb level, CO-oximetry (pulse ox invalid)</p></td>
<td class="bg0-b"><p class="tab">100% normobaric oxygen, hyperbaric O<sub class="calibre13">2</sub> in severe cases</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Organophosphate</b></p></td>
<td class="bg0-br"><p class="tab">Salivation, lacrimation, diaphoresis, miosis, emesis, bronchospasm, ΔMS</p></td>
<td class="bg0-b"><p class="tab">Endotracheal intubation for respiratory failure, atropine, pralidoxime, benzodiazepines</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Cyanide</b></p></td>
<td class="bg0-r"><p class="tab">Coma, seizure, metabolic acidosis, hypotension</p></td>
<td class="bg"><p class="tab">IV Na nitrite and Na thiosulfate</p>
<p class="tab">IV hydroxocobalamin</p></td>
</tr>
</table>
<p class="tsr">(<i class="calibre3">Chest</i> 2011;140:1072)</p>
<h2 class="ct"><a id="h38" class="calibre7"></a><a href="part0002.html#rh43" class="calibre7">LUNG TRANSPLANT</a></h2>
<p class="h2a">Overview</p>
<p class="bl"><span class="sbl">•</span> Indications: end stage, progressive decline despite max medical Rx, &lt;2-y life expectancy; COPD, ILD (IPF), pulmonary HTN, cystic fibrosis, alpha 1-antitrypsin</p>
<p class="bl"><span class="sbl">•</span> Contraindic: age &gt;65 (rel.), uncontrolled/unRx’d infxn, malig in prior 2 y, severe non-pulm dis., BMI ≥35, active smoking, EtOH/drug depend., med noncompliance, psychosocial</p>
<p class="h2a">Posttransplant care</p>
<p class="bl"><span class="sbl">•</span> Immunosuppression: center dependent; no single best regimen. Tacro &gt; cyclosporine (↓ incidence of acute rejection) + steroids + MMF/azathioprine</p>
<p class="bl"><span class="sbl">•</span> Monitoring: clinic visits, serial PFTs, chest X-ray, bronchoscopy w/ transbronchial biopsy</p>
<p class="h2a">Complications</p>
<p class="bl"><span class="sbl">•</span> Primary graft dysfunction (PGD): acute lung injury following txp; assoc w/ early mortality</p>
<p class="bl"><span class="sbl">•</span> Anastomotic: vascular (stenosis, thrombosis) and airway (infection, necrosis, dehiscence, granulation tissue, tracheobronchomalacia, stenosis, fistula)</p>
<p class="bl"><span class="sbl">•</span> Acute rejection: ↓ lung fxn, cough, SOB, fever; Dx w/ trans-bronch bx; Rx immunosupp</p>
<p class="bl"><span class="sbl">•</span> Chronic rejection: bronchiolitis obliterans w/ obstruction; Dx w/ PFTs, trans-bronch bx; Rx limited (azithromycin, montelukast, Δ immunosuppressives)</p>
<p class="bl"><span class="sbl">•</span> Infection: ↑ bacterial, fungal, viral pneumonia, systemic infections, CMV, OI</p>
<p class="bl"><span class="sbl">•</span> Malignancy: 2× ↑ risk overall. 5.5× ↑ risk lung cancer. PTLD (assoc w/ EBV) common.</p>
<p class="bl"><span class="sbl">•</span> Misc: GVHD, CKD, DM, CAD, CHF, stroke, encephalopathy, drug toxicity</p>


  </div>

  
  <div class="calibreToc">
    <h2><a href="../../k34gmbu8.html">Table of contents
</a></h2>
    <div>
  <ul>
    <li>
      <a href="part0000.html#0-74951b69f9a94472af57c47504abb1f1">Title Page</a>
    </li>
    <li>
      <a href="part0001.html#UGI0-74951b69f9a94472af57c47504abb1f1">Copyright Page</a>
    </li>
    <li>
      <a href="part0002.html#1T140-74951b69f9a94472af57c47504abb1f1">Contents</a>
    </li>
    <li>
      <a href="part0003.html#2RHM0-74951b69f9a94472af57c47504abb1f1">Contributing Authors</a>
    </li>
    <li>
      <a href="part0004.html#3Q280-74951b69f9a94472af57c47504abb1f1">Foreword</a>
    </li>
    <li>
      <a href="part0005.html#4OIQ0-74951b69f9a94472af57c47504abb1f1">Preface</a>
    </li>
    <li>
      <a href="part0006.html#5N3C0-74951b69f9a94472af57c47504abb1f1">Cardiology</a>
      <ul>
        <li>
          <a href="part0006.html#h1">Electrocardiography</a>
        </li>
        <li>
          <a href="part0006.html#h2">Chest Pain</a>
        </li>
        <li>
          <a href="part0006.html#h3">Noninvasive Evaluation of CAD</a>
        </li>
        <li>
          <a href="part0006.html#h4">Coronary Angiography and Revascularization</a>
        </li>
        <li>
          <a href="part0006.html#h5">Acute Coronary Syndromes</a>
        </li>
        <li>
          <a href="part0006.html#h6">PA Catheter and Tailored Therapy</a>
        </li>
        <li>
          <a href="part0006.html#h7">Heart Failure</a>
        </li>
        <li>
          <a href="part0006.html#h8">Cardiomyopathies</a>
        </li>
        <li>
          <a href="part0006.html#h9">Valvular Heart Disease</a>
        </li>
        <li>
          <a href="part0006.html#h10">Pericardial Disease</a>
        </li>
        <li>
          <a href="part0006.html#h11">Hypertension</a>
        </li>
        <li>
          <a href="part0006.html#h12">Aortic Aneurysms</a>
        </li>
        <li>
          <a href="part0006.html#h13">Acute Aortic Syndromes</a>
        </li>
        <li>
          <a href="part0006.html#h14">Arrhythmias</a>
        </li>
        <li>
          <a href="part0006.html#h15">Atrial Fibrillation</a>
        </li>
        <li>
          <a href="part0006.html#h16">Syncope</a>
        </li>
        <li>
          <a href="part0006.html#h17">Cardiac Rhythm Management Devices</a>
        </li>
        <li>
          <a href="part0006.html#h18">Cardiac Risk Assessment for Noncardiac Surgery</a>
        </li>
        <li>
          <a href="part0006.html#h19">Peripheral Artery Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0007.html#6LJU0-74951b69f9a94472af57c47504abb1f1">Pulmonary</a>
      <ul>
        <li>
          <a href="part0007.html#h20">Dyspnea</a>
        </li>
        <li>
          <a href="part0007.html#h21">Pulmonary Function Tests</a>
        </li>
        <li>
          <a href="part0007.html#h22">Asthma</a>
        </li>
        <li>
          <a href="part0007.html#h23">Anaphylaxis</a>
        </li>
        <li>
          <a href="part0007.html#h24">Chronic Obstructive Pulmonary Disease</a>
        </li>
        <li>
          <a href="part0007.html#h25">Solitary Pulmonary Nodule</a>
        </li>
        <li>
          <a href="part0007.html#h26">Hemoptysis</a>
        </li>
        <li>
          <a href="part0007.html#h27">Bronchiectasis</a>
        </li>
        <li>
          <a href="part0007.html#h28">Cystic Fibrosis</a>
        </li>
        <li>
          <a href="part0007.html#h29">Interstitial Lung Disease</a>
        </li>
        <li>
          <a href="part0007.html#h30">Pleural Effusion</a>
        </li>
        <li>
          <a href="part0007.html#h31">Venous Thromboembolism</a>
        </li>
        <li>
          <a href="part0007.html#h32">Pulmonary Hypertension</a>
        </li>
        <li>
          <a href="part0007.html#h33">Respiratory Failure</a>
        </li>
        <li>
          <a href="part0007.html#h34">Mechanical Ventilation</a>
        </li>
        <li>
          <a href="part0007.html#h35">Acute Respiratory Distress Syndrome</a>
        </li>
        <li>
          <a href="part0007.html#h36">Sepsis and Shock</a>
        </li>
        <li>
          <a href="part0007.html#h37">Toxicology</a>
        </li>
        <li>
          <a href="part0007.html#h38">Lung Transplant</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0008.html#7K4G0-74951b69f9a94472af57c47504abb1f1">Gastroenterology</a>
      <ul>
        <li>
          <a href="part0008.html#h39">Esophageal and Gastric Disorders</a>
        </li>
        <li>
          <a href="part0008.html#h40">Gastrointestinal Bleeding</a>
        </li>
        <li>
          <a href="part0008.html#h41">Diarrhea</a>
        </li>
        <li>
          <a href="part0008.html#h42">Dysmotility &amp; Nutrition</a>
        </li>
        <li>
          <a href="part0008.html#h43">Disorders of the Colon</a>
        </li>
        <li>
          <a href="part0008.html#h44">Inflammatory Bowel Disease</a>
        </li>
        <li>
          <a href="part0008.html#h45">Intestinal Ischemia</a>
        </li>
        <li>
          <a href="part0008.html#h46">Pancreatitis</a>
        </li>
        <li>
          <a href="part0008.html#h47">Abnormal Liver Tests</a>
        </li>
        <li>
          <a href="part0008.html#h48">Hepatitis</a>
        </li>
        <li>
          <a href="part0008.html#h49">Acute Liver Failure</a>
        </li>
        <li>
          <a href="part0008.html#h50">Cirrhosis</a>
        </li>
        <li>
          <a href="part0008.html#h51">Hepatic Vascular Disease</a>
        </li>
        <li>
          <a href="part0008.html#h52">Ascites</a>
        </li>
        <li>
          <a href="part0008.html#h53">Biliary Tract Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0009.html#8IL20-74951b69f9a94472af57c47504abb1f1">Nephrology</a>
      <ul>
        <li>
          <a href="part0009.html#h54">Acid-Base Disturbances</a>
        </li>
        <li>
          <a href="part0009.html#h55">Sodium and Water Homeostasis</a>
        </li>
        <li>
          <a href="part0009.html#h56">Potassium Homeostasis</a>
        </li>
        <li>
          <a href="part0009.html#h57">Renal Failure</a>
        </li>
        <li>
          <a href="part0009.html#h58">Glomerular Disease</a>
        </li>
        <li>
          <a href="part0009.html#h59">Urinalysis</a>
        </li>
        <li>
          <a href="part0009.html#h60">Nephrolithiasis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0010.html#9H5K0-74951b69f9a94472af57c47504abb1f1">Hematology-Oncology</a>
      <ul>
        <li>
          <a href="part0010.html#h61">Anemia</a>
        </li>
        <li>
          <a href="part0010.html#h62">Disorders of Hemostasis</a>
        </li>
        <li>
          <a href="part0010.html#h63">Platelet Disorders</a>
        </li>
        <li>
          <a href="part0010.html#h64">Coagulopathies</a>
        </li>
        <li>
          <a href="part0010.html#h65">Hypercoagulable States</a>
        </li>
        <li>
          <a href="part0010.html#h66">Disorders of Leukocytes</a>
        </li>
        <li>
          <a href="part0010.html#h67">Transfusion Therapy</a>
        </li>
        <li>
          <a href="part0010.html#h68">Myelodysplastic Syndromes</a>
        </li>
        <li>
          <a href="part0010.html#h69">Myeloproliferative Neoplasms</a>
        </li>
        <li>
          <a href="part0010.html#h70">Leukemia</a>
        </li>
        <li>
          <a href="part0010.html#h71">Lymphoma</a>
        </li>
        <li>
          <a href="part0010.html#h72">Plasma Cell Dyscrasias</a>
        </li>
        <li>
          <a href="part0010.html#h73">Hematopoietic Stem Cell Transplantation</a>
        </li>
        <li>
          <a href="part0010.html#h74">Lung Cancer</a>
        </li>
        <li>
          <a href="part0010.html#h75">Breast Cancer</a>
        </li>
        <li>
          <a href="part0010.html#h76">Prostate Cancer</a>
        </li>
        <li>
          <a href="part0010.html#h77">Colorectal Cancer</a>
        </li>
        <li>
          <a href="part0010.html#h78">Pancreatic Tumors</a>
        </li>
        <li>
          <a href="part0010.html#h79">Hepatocellular Carcinoma (HCC)</a>
        </li>
        <li>
          <a href="part0010.html#h80">Oncologic Emergencies</a>
        </li>
        <li>
          <a href="part0010.html#h81">Chemotherapy &amp; Immunotherapy Side Effects</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0011.html#AFM60-74951b69f9a94472af57c47504abb1f1">Infectious Diseases</a>
      <ul>
        <li>
          <a href="part0011.html#h82">Pneumonia</a>
        </li>
        <li>
          <a href="part0011.html#h83">Fungal Infections</a>
        </li>
        <li>
          <a href="part0011.html#h84">Infections in Immunosuppressed Hosts</a>
        </li>
        <li>
          <a href="part0011.html#h85">Urinary Tract Infections</a>
        </li>
        <li>
          <a href="part0011.html#h86">Soft Tissue and Bone Infections</a>
        </li>
        <li>
          <a href="part0011.html#h87">Infections of the Nervous System</a>
        </li>
        <li>
          <a href="part0011.html#h88">Bacteremia &amp; Endocarditis</a>
        </li>
        <li>
          <a href="part0011.html#h89">Tuberculosis</a>
        </li>
        <li>
          <a href="part0011.html#h90">HIV/AIDS</a>
        </li>
        <li>
          <a href="part0011.html#h91">Tick-Borne Diseases</a>
        </li>
        <li>
          <a href="part0011.html#h92">Fever Syndromes</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0012.html#BE6O0-74951b69f9a94472af57c47504abb1f1">Endocrinology</a>
      <ul>
        <li>
          <a href="part0012.html#h93">Pituitary Disorders</a>
        </li>
        <li>
          <a href="part0012.html#h94">Thyroid Disorders</a>
        </li>
        <li>
          <a href="part0012.html#h95">Adrenal Disorders</a>
        </li>
        <li>
          <a href="part0012.html#h96">Calcium Disorders</a>
        </li>
        <li>
          <a href="part0012.html#h97">Diabetes Mellitus</a>
        </li>
        <li>
          <a href="part0012.html#h98">Lipid Disorders</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0013.html#CCNA0-74951b69f9a94472af57c47504abb1f1">Rheumatology</a>
      <ul>
        <li>
          <a href="part0013.html#h99">Approach to Rheumatic Disease</a>
        </li>
        <li>
          <a href="part0013.html#h100">Rheumatoid Arthritis</a>
        </li>
        <li>
          <a href="part0013.html#h101">Adult-Onset Still’s Disease &amp; Relapsing Polychondritis</a>
        </li>
        <li>
          <a href="part0013.html#h102">Crystal Deposition Arthritides</a>
        </li>
        <li>
          <a href="part0013.html#h103">Seronegative Spondyloarthritis</a>
        </li>
        <li>
          <a href="part0013.html#h104">Infectious Arthritis &amp; Bursitis</a>
        </li>
        <li>
          <a href="part0013.html#h105">Connective Tissue Diseases</a>
        </li>
        <li>
          <a href="part0013.html#h106">Systemic Lupus Erythematosus</a>
        </li>
        <li>
          <a href="part0013.html#h107">Vasculitis</a>
        </li>
        <li>
          <a href="part0013.html#h108">IgG4-Related Disease</a>
        </li>
        <li>
          <a href="part0013.html#h109">Cryoglobulinemia</a>
        </li>
        <li>
          <a href="part0013.html#h110">Amyloidosis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0014.html#DB7S0-74951b69f9a94472af57c47504abb1f1">Neurology</a>
      <ul>
        <li>
          <a href="part0014.html#h111">Change in Mental Status</a>
        </li>
        <li>
          <a href="part0014.html#h112">Seizures</a>
        </li>
        <li>
          <a href="part0014.html#h113">Alcohol Withdrawal</a>
        </li>
        <li>
          <a href="part0014.html#h114">Dizziness</a>
        </li>
        <li>
          <a href="part0014.html#h115">Stroke</a>
        </li>
        <li>
          <a href="part0014.html#h116">Weakness &amp; Neuromuscular Dysfunction</a>
        </li>
        <li>
          <a href="part0014.html#h117">Headache</a>
        </li>
        <li>
          <a href="part0014.html#h118">Back and Spinal Cord Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0015.html#E9OE0-74951b69f9a94472af57c47504abb1f1">Consults</a>
      <ul>
        <li>
          <a href="part0015.html#h119">Surgical Issues</a>
        </li>
        <li>
          <a href="part0015.html#h120">Ob/Gyn Issues</a>
        </li>
        <li>
          <a href="part0015.html#h121">Ophthalmic Issues</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0016.html#F8900-74951b69f9a94472af57c47504abb1f1">Appendix</a>
      <ul>
        <li>
          <a href="part0016.html#h122">ICU Medications &amp; Treatment of Hypotension/Shock</a>
        </li>
        <li>
          <a href="part0016.html#h123">Antibiotics</a>
        </li>
        <li>
          <a href="part0016.html#h124">Formulae and Quick Reference</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0017.html#G6PI0-74951b69f9a94472af57c47504abb1f1">Abbreviations</a>
    </li>
    <li>
      <a href="part0018.html#H5A40-74951b69f9a94472af57c47504abb1f1">Index</a>
    </li>
    <li>
      <a href="part0019.html#I3QM0-74951b69f9a94472af57c47504abb1f1">Photo Inserts</a>
      <ul>
        <li>
          <a href="part0019.html#h125">Radiology</a>
        </li>
        <li>
          <a href="part0019.html#h126">Echocardiography &amp; Coronary Angiography</a>
        </li>
        <li>
          <a href="part0019.html#h127">Peripheral Blood Smears &amp; Leukemias</a>
        </li>
        <li>
          <a href="part0019.html#h128">Urinalysis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0022.html#KVCC0-74951b69f9a94472af57c47504abb1f1">ACLS</a>
    </li>
  </ul>
</div>


  </div>
  

  <div class="calibreEbNav">
    
      <a href="part0006.html" class="calibreAPrev">previous page
</a>
    

    <a href="../../k34gmbu8.html" class="calibreAHome">start
</a>

    
      <a href="part0008.html" class="calibreANext">next page
</a>
    
  </div>

</div>

</body>
</html>
